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INTRODUCTION*
Rheumatoid Arthritis (RA)
Treatment of RA
RA is a chronic inflammatory systemic disease, mainly characterised by synovitis
of small joints, especially of hands and feet.1 Persistent synovitis leads to pain,
joint swelling, stiffness, decreased mobility and joint space narrowing; synovial
hyperplasia causes erosions and joint deformities.2 Extra-articular as well as systemic
features may occur.1 Pain, loss of physical functioning, fatigue and other symptoms
of RA have a major impact on social life. The disease is costly to individuals,
families and society in both economic and social terms.
The aetiology of RA is still incompletely known; a multiplicity of genetic,
environmental, immunologic and psychoneuroendocrine factors like dysfunction
of the hypothalamic-pituitary-adrenal (HPA-) axis plays a role.3-5 An initial infectious
event could be involved but there is no convincing evidence for this hypothesis.1
Irreversible joint damage of patients with RA often starts within the first two years
of the disease.2, 6-9 Joint damage in RA consists on the one hand of cartilage thinning
with joint space narrowing and on the other hand of erosions as a characteristic
feature of bone destruction. In the pathogenesis of joint damage, T-cells and
macrophages and their products in the hyperplastic rheumatoid synovial lining
layer play a major role. T-cells and macrophages produce cytokines as interleukin-
1 (IL-1) and tumor necrosis factor alpha (TNF-α) that drive the inflammatory and
destructive processes in RA. In addition, macrophages and fibroblasts produce
proteolytic enzymes such as matrix metalloproteinases (MMPs), which are thought
to be of particular importance in the development of joint erosions.10
Treatment of RA
Patients with RA are best treated by a rheumatologist participating in a
multidisciplinary team of specialised health professionals, including a physical
therapist, occupational therapist, nurse practitioner in rheumatology and a medical
(psycho-) social worker. Orthopedic and reconstructive surgery can play an
important role in relieving pain and in restoring or maintaining physical function.
Guarded intensive physical training in groups is a recently developed additional
strategy.11
* Part of this introduction has been published 15, 46, 47
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Drug treatment of RA usually consists of a combination of a non-steroidal anti-
inflammatory drug (NSAID) and a disease-modifying anti-rheumatic drug
(DMARD), for instance hydroxychloroquine, sulphasalazine, methotrexate,
ciclosporin, leflunomide or a combination of DMARDs. New biological agents,
such as tumor necrosis factor (TNF)-alpha blockers and interleukin-1 (IL-1) receptor
antagonists, are promising.12, 13 Glucocorticoids (GC) have a special place in the
treatment of RA and will be discussed in detail, as they are the focus of this thesis.
Glucocorticoids in RA
GC are widely used in the treatment of patients with RA since the initial report by
Hench et al. that cortisone dramatically ameliorated the symptoms of RA.14
A period of enthusiasm in the fifties about the effects of GC was followed by a
long period of cautious application of GC for RA, because of the many side
effects. Despite the continuing debate about the risks and benefits GC are considered
by many patients with RA, as well as by their physicians, to be most effective
symptomatic drugs, and their anti-inflammatory properties are well established.
New insights in the mechanism of GC, especially their effects on the immune
system and the hypothalamic pituitary adrenal (HPA) axis, have provided justification
for discretionary use of these drugs in RA.15-17 Fundamental research continues to
unravel the complexity of the biological effects of GC, such as on gene transcription,
and careful clinical observations refine their therapeutic use.18
The role of the glucocorticoid receptor (GR) in RA
The HPA-axis plays a crucial role in the homeostasis of the human body, including
regulation of inflammation. GC have potent anti-inflammatory actions through their
influence on the HPA- axis and the stress response. In this way, GC influence
nearly all cells and organ systems.15 GC exert their effects through the GC receptor
(GR) located in the cytoplasm of target cells at low doses.16 At higher doses,
genomic (i.e. through the GR) as well as non-genomic modes of action play a role. 19
Schlaghecke et al. showed a diminished GR-number (sites/cell) in peripheral blood
mononuclear leucocytes (PBMC) of RA patients with active disease of longer
duration (mean 6 years) compared to healthy controls.20 In contrast, Sanden et al.
showed an increase in the number of GRs in patients with a large range of disease
activity compared to healthy controls. This increased number decreased on GC
therapy in a dose dependent way.21
In daily clinical practice, not all patients do respond in the same way to GC
treatment: some do not respond at all, others do at low doses, while others require
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larger doses for seemingly identical clinical situations. In a study of lupus patients
with nephrotic syndrome treated with GC, a distinct effect of GR level was observed
on the clinical responsiveness to GC therapy.22 Steroid resistant asthma patients
show abnormalities of GR-expression.23 So, the GR number of PBMC might be
helpful to predict which RA patients will respond to low dose prednisone and
which patients need higher doses.
Clinical data on GC in RA
In daily practice, GC seem to have greatest effect on morning stiffness and other
systemic symptoms, such as fatigue, weakness and anorexia. An increase in
haemoglobin concentration is noted, together with a decrease in erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP). Walking time and grip
strength of the hands often increase. Joint inflammation is more variably influenced.
In cases of extra-articular disease, such as pericarditis and pleuritis, GC are effective,
but often medium to high dosages are necessary to control these complications. At
present, the use of long-term treatment with low-dose GC in clinical practice is
different from country to country and estimated to range from 25 up till 75% of
patients with longstanding RA.24, 25 Nevertheless, this use of oral low-dose GC in
the treatment of RA gives rise to continued debate. Low-dose GC (prednisone
≤ 7.5 mg/day) effectively and rapidly suppress signs and symptoms of inflammation
in RA, but adverse effects limit their role.25 In the opinion of most physicians and
patients, the beneficial effects of low-dose GC seem to outweigh their adverse
effects.26
Clinical studies on GC in RA
Numerous short-term studies have demonstrated the ability of low-doses of GC to
partly suppress the signs and symptoms of inflammation of patients with active
RA. Only a limited number of studies has evaluated the effect of these agents
versus placebo or NSAIDs for more than 3 months.16 In 1996 a systemic review
and a meta-analysis of the effectiveness of low-dose GC for the treatment of RA
were published.27 Only 9 studies were identified that fulfilled the set criteria:
randomised, controlled, parallel or crossover trials lasting 3 months or longer using
GC at a mean dosage of less than or equal to 15 mg/daily. Four were placebo-
controlled and the other 5 were active drug-controlled studies comparing the effect
of prednisone with that of another agent. Outcome measures included the number
of tender and swollen joints and ESR. From the multiple publications of the Empire
Rheumatism Council and the Joint Commission of the Medical Research Council
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and Nuffield Foundation, one study was included comparing the effects of cortisone
with those of aspirin and one comparing the effect of prednisone with that of
aspirin.28, 29 From these meta-analyses it is suggested that GC appear to be more
effective than placebo and are nearly equivalent to traditional DMARDs in improving
most of the conventional outcome measures. However, data were limited; the
treatment episodes were relatively short (7 months on average) and the GC were
given late in course of the disease and often in combination with DMARDs.
So, the widespread use of low-dose GC in RA is still based on a rather low
number of controlled studies. However, they generally uphold the widely held belief
that low-dose GC are effective in the treatment of RA.2 Until recently almost all
studies with GC treatment are conducted in patients with RA of longer duration
(mostly more than several years). In the past few years studies were performed
among patients with early RA.
Joint protective properties of GC in RA
The review by Weiss in 1989 of GC treatment in RA, in which disease modifying
properties were addressed, was followed by renewed clinical and scientific interest
in these drugs, especially since potential serious adverse and side effects of GC
therapy are more easily managed nowadays.30,31
In 1995 Kirwan demonstrated a significant reduction in progression of
radiologically detected joint damage of the hands, if GC were added to antirheumatic
treatment in a double-blind placebo-controlled study among 128 patients with early
RA.8 Patients received prednisone (7.5 mg daily) or placebo for 2 years in addition
to NSAIDs (95% of patients) and DMARDs (71% of patients). After 2 years both
the mean total number of erosions and the number of patients with erosions were
significantly lower in the GC group. Improvement in clinical parameters was found
only during the first year of therapy. It was concluded that a fixed daily dose of 7.5
mg given as adjuvant therapy for early active RA retards radiological progression
of joint destruction.  However, only hands were evaluated for the radiological
score. In the follow-up study of the same patients joint destruction resumed at the
previous rate at a lower level after tapering and discontinuation of prednisone.32
Zeidler et al. performed a study in 192 patients with early RA. In this double-
blind placebo-controlled trial of patients treated with gold sodium thiomalate or
methotrexate, the effect of 5 mg daily of adjuvant prednisolone therapy was
evaluated.33 Prednisolone proved to be effective in further reducing inflammatory
symptoms as well as radiological progression of erosions, confirming the data of
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Kirwan et al. In the COBRA study of early RA, Boers et al. compared the effect of
a combined step-down strategy with prednisone, methotrexate and sulphasalazine
with that of sulphasalazine monotherapy.34 The combined therapeutic regimen with
prednisone (initially 60mg/day, tapered every 6 weeks to 7.5 mg/day and stopped
at week 28) slowed down radiological damage significantly more than sulphasalazine
alone at weeks 28, 56 and 80. Patients in the prednisone group also showed rapid
disease control as measured by tender joint count, grip strength, overall assessment
by the independent assessor on a 100 mm visual analogue scale, McMaster Toronto
arthritis questionnaire, and ESR. After stopping the prednisone treatment at 26
weeks, these indices became comparable with those of the sulphasalazine only
group. Other studies in RA patients, comparing effects of treatment with
sulphasalazine, methotrexate or a combination of both, did not show such significant
differences in effect between these therapeutic regimens in retardation of
radiologically detected joint damage suggesting that the joint-sparing effect in the
study of Boers is based on the GC-therapy.35, 36 The follow-up COBRA study
showed sustained suppression of the rate of radiological progression in patients
with early RA, independent of subsequent antirheumatic therapy in contrast to the
study of Kirwan.37 So, several studies suggest that prednisone is the potent inhibitor
of joint damage.
Effects of GC on general wellbeing of RA patients
There are indications for dysfunction of the HPA axis at the hypothalamic level in
RA.4, 5 Due to this, the stress response may be influenced, modifying the autonomic
system and behavioural adaptation.15, 38 In several studies of patients with RA,
treated with GC, parameters such as pain and physical ability ameliorated.8, 32, 39 In
one study with short term high-dose GC treatment of patients with active RA a
positive effect on disease activity, physical ability, psychological and social
functioning as well as the impact on daily life was described.40
However, relatively little is known about the long-term effects of GC on
parameters of wellbeing.41
Adverse and Side Effects of GC (also Table 1.)
Given the diversity of their mechanisms and sites of action, it is not surprising that
GC can cause a wide array of adverse and side effects, some of which cannot be
completely avoided. Theoretically, the risk for most of these complications is dosage
and time-dependent. It is a striking clinical observation that some patients develop
CHAPTER 1
8
TABLE 1
Adverse effects of GC therapy 46
Onset early in therapy
Emotional lability, Insomnia
Enhanced appetite, weight gain
Enhanced in patients with genetic predisposition such as diabetes mellitus and underlying risk factors or concomitant
use of other drugs
Acne vulgaris
Diabetes mellitus
Hypertension
Peptic ulcer disease
When supraphysiologic GC treatment is sustained
Cushingoid appearance
Hypothalamic-pituitary-adrenal suppression, adrenal insufficiency
Impaired wound healing
Myopathy, muscular atrophy, skin atrophy
Osteonecrosis
Immunosuppression, Predisposition to infections
Glaucoma
Delayed and insidious, probably dependent on cumulative doses
Atherosclerosis
Cataract
Steatosis hepatis
Growth retardation in children
Loss of scalp hair and (more often) thinning of scalp hair
Skin atrophy with easy bruisability of skin
Osteoporosis
Less frequent or less predictable
Pancreatitis
Pseudotumor cerebri
Psychosis
severe adverse effects with relatively small doses of GC, while other patients receive
rather high doses without obvious serious adverse effects. This apparent individual
susceptibility for adverse effects does not seem to parallel the individual’s
susceptibility for beneficial effects.
The toxicity of prednisone of 15 mg or less for at least 1 year in the treatment of
RA has been evaluated.42 Although disease severity is an important confounding
factor in interpreting this evaluation, 3 serious (groups of) adverse events were
identified that caused substantial morbidity: gastrointestinal ulcers and/or bleeding
or ulcers, infections and osteopenia/osteoporosis.
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RATIONALE OF THE THESIS
In recent years, therapeutic approaches of patients with RA are aimed at more early
phases of the disease in order to reduce or prevent joint damage.43-45 In daily
practice, GC are widely used in combination with disease-modifying drugs to
diminish disease activity and to relief symptoms.26 Because of adverse and side
effects, courses with GC therapy are generally short with the lowest possible dosis.
Recent studies with combination therapies support the hypothesis that GC in itself
have disease-modifying properties.27-29, 32
To investigate the disease-modifying properties of GC, without interference of
DMARDs, we performed a double-blind, placebo controlled, 2-year study (and
1 year follow-up) with low-dose GC as monotherapy in DMARD naive patients
with early active RA, in contrast to other studies where GC were added to DMARDs.
The results of this study with focus on retardation of joint damage in relation to
parameters of disease activity and side effects will be addressed in Chapter 2.46
We assessed in our study in more detail the effects of low-dose GC therapy of
patients with early RA on bone and fracture rate (Chapter 3).
The effects of GC on wellbeing in patients with early RA were investigated and the
role of the use of additional therapies in assessing parameters of wellbeing was
also evaluated (Chapter 4).
In literature a diminished GR number was described in patients with RA of longer
duration. This could especially be present in patients with early-diagnosed RA. To
investigate the hypothesis that GR-downregulation might play a role in the
etiopathogenesis of RA as a result of impairment of the HPA-axis, we compared
the GR-expression as well as the serum cortisol levels of early RA patients with
those of sex-and age-matched healthy controls (Chapter 5).
To investigate the hypothesis that early RA patients with a higher GR-number
might respond better clinically to low dose prednisone than patients with a lower
GR-number, we investigated whether there was a relation between the GR-number
in peripheral blood mononuclear cells (PBMC) determined at baseline in patients
with early RA treated with 10 mg prednisone and the clinical effect of the prednisone
therapy during the 2 years of treatment (Chapter 6).
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Abstract
Background
Oral glucocorticoids combined with disease-modifying antirheumatic drugs are
beneficial and retard radiologic joint damage in rheumatoid arthritis.
Objective
To investigate the clinical efficacy, disease-modifying properties and side effects
of low-dose glucocorticoids as monotherapy for previously untreated patients with
early active rheumatoid arthritis.
Design
2-year randomized, double-blind, placebo-controlled clinical trial.
Setting
2 outpatient rheumatology clinics.
Patients
81 patients with early active rheumatoid arthritis who had not been treated with
disease-modifying antirheumatic drugs.
Intervention
41 patients were assigned to 10 mg of oral prednisone per day, and 40 were assigned
to placebo. Nonsteroidal anti-inflammatory drugs were allowed in both groups.
After 6 months, sulfasalazine (2 g/d) could be prescribed as rescue medication.
Measurements
Clinical variables were assessed at baseline and every 3 months; radiologic studies
were performed every 6 months. Adverse effects were documented every 3 months.
Results
In the first 6 months, the prednisone group showed more clinical improvement
than the placebo group. This effect was not seen after 6 months except in grip
strength and the 28-joint score for tenderness. Use of additional therapies was
significantly less common in the prednisone group, particularly in the first 6 months.
More than 65% of those who completed the study were not taking sulfasalazine.
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After month 6, radiologic scores showed significantly less progression in the
prednisone group than in the placebo group. No clinically relevant adverse effects
were observed, except for a higher incidence of osteoporotic fractures in the
prednisone group.
Conclusions
Prednisone, 10 mg/d, provides clinical benefit, particularly in the first 6 months,
and substantially inhibits progression of radiologic joint damage in patients with
early active rheumatoid arthritis and no previous treatment with disease-modifying
antirheumatic drugs. Because of their limited disease-modifying effects,
glucocorticoids should be combined with disease-modifying antirheumatic drugs
in patients with rheumatoid arthritis.
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INTRODUCTION
Drug treatment for rheumatoid arthritis usually consists of a combination of a
nonsteroidal anti-inflammatory drug (NSAID) and a disease-modifying antirheumatic
drug (for example, sulfasalazine, methotrexate, gold salt, or a combination). New
biological agents, such as tumor necrosis factor-α blocking agents and interleukin-1
receptor antagonists, appear promising.1,2 Glucocorticoids have had a special place
in the treatment of rheumatoid arthritis since the publication of the report by Hench
and coworkers showing that cortisone dramatically alleviated the symptoms of
rheumatoid arthritis by inhibiting inflammation.3 This period of enthusiasm in the
1950s was followed by a long period in which glucocorticoids were applied
cautiously for rheumatoid arthritis because of their many side effects and the
recognition that inhibition of inflammation is not necessarily associated with
retardation of joint damage.4
Ongoing research on glucocorticoids in rheumatoid arthritis focused on both
inflammation and joint damage. Some recent studies showed that glucocorticoids
reduced the progression of joint damage when added to therapy with disease-
modifying antirheumatic drugs. These findings suggested that glucocorticoids might
also have disease-modifying properties. If this could be confirmed, glucocorticoids
might be used more often, especially since potential serious adverse effects of
glucocorticoid therapy are more easily managed today.5 Secondary osteoporosis
is inhibited by potent bisphosphonates, and gastro-intestinal complications of
glucocorticoid therapy, especially in combination with NSAIDs, can be reduced
by misoprostol, proton-pump inhibitors, or cyclo-oxygenase-2 selective NSAIDs.
As yet, disease-modifying properties of low-dose glucocorticoids as monotherapy
for patients with early rheumatoid arthritis have not been investigated. The aim of
our study was to investigate the clinical efficacy, disease-modifying properties,
and side effects of low-dose glucocorticoids as monotherapy for previously
untreated patients with early active rheumatoid arthritis.
METHODS
Patients
From October 1992 through October 1995, all consecutive outpatients at the
rheumatology departments of the Deventer and Zutphen Hospitals, the Netherlands,
who were at least 18 years of age and had early previously untreated rheumatoid
arthritis (disease duration < 1 year) that satisfied classification criteria were invited
to participate in the study.6 To be included, patients had to have active disease,
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which was defined as the presence of at least two of the following three criteria: 1)
early-morning stiffness lasting 30 minutes or longer, 2) 28-joint score for tenderness
and 28-joint score for swelling of 3 or more, and 3) Westergren erythrocyte
sedimentation rate of 28 mm or higher after 1 hour.7,8 Exclusion criteria were
contraindications to prednisone or NSAIDs, active gastrointestinal problems, serious
complicating diseases, severe hypertension, hemorrhagic diathesis, treatment with
cytotoxic or immunosuppressive drugs, alcohol or drug abuse, and psychiatric or
mental problems. Informed consent was obtained from all patients before
participation. Of the 118 eligible patients, 37 declined to participate (Figure 1).
Intervention
Pharmacy personnel at Deventer Hospital used a computer-generated randomization
procedure to randomly assign the 81 participating patients, in blocks of 10, to one
of two treatment groups. One group received two tablets of prednisone, 5 mg,
once daily at breakfast, and one group received placebo. The pharmacology
department at Deventer Hospital prepared and labeled the prednisone and placebo
tablets, which were identical in shape and color, and distributed them to patients in
unlabeled boxes. Only the pharmacist could access the allocation table. Both groups
of patients received 500 mg of elementary calcium in the evening. The code of
randomization was broken after 2 years of treatment, and the prednisone dosage
was tapered. Surplus tablets of the study medication were counted at every visit,
and adherence was satisfactory (96%). Use of NSAIDs was not regulated. Local
glucocorticoid injections were permitted only when absolutely necessary. Physical
therapy and additional use of paracetamol were allowed. After 6 months, sulfasalazine
(2 g/d) could be prescribed as rescue medication. The decision to add sulfasalazine
was made on clinical grounds (activity of rheumatoid arthritis).
Design and Setting
The ethics committees of the University Medical Center Utrecht and the Deventer
and Zutphen Hospitals approved the trial. The study was considered ethically
acceptable when it was designed (1989 –1991); later, however, it became clear that
irreversible joint damage is an early feature of rheumatoid arthritis. With our present
knowledge, it would probably be considered unethical to compare the effects of
prednisone and placebo in patients who did not receive a disease-modifying
antirheumatic drug for at least 6 months. In our study, sulfasalazine could be
prescribed as rescue medication only after 6 months to avoid obscuring the effects
of prednisone monotherapy.
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Patients eligible for study (n = 118) Declined (n = 37)
Placebo group (n = 41) Prednisone group (n = 40)
Month 6
Participating (n = 38)
Dead  from vasculitis (n = 1)
Ischemic  cerebrovascular accident (n = 1)
Month 9
Participating (n = 36)
Ischemic  cerebrovascular accident (n = 1)
Loss of motivation (n = 1)
Month 12
Participating (n = 35)
Cervix carcinoma (n = 1)
Month 3
Participating (n = 40)
Dead  from vasculitis (n = 1)
Randomly assigned  (n = 81)
Month 12
Participating (n = 39)
Loss of motivation (n = 1)
Month 15
Participating (n = 38)
Emigrated (n = 1)
Month 21
Participating (n = 36)
Dead from myocardial infarction (n = 1)
Alcohol abuse (n = 1)
Completed trial
at month 24 (n = 36)
Completed trial
at month 24 (n = 35)
FIGURE 1. Trial profile.
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Measurements
All clinical outcome measurements, except those for disability and radiologic
outcomes, were performed at baseline and every 3 months. Disability, which was
assessed with the Health Assessment Questionnaire, and radiologic outcomes were
measured every 6 months. Early-morning stiffness was recorded in minutes
(maximum, 720 minutes). Morning pain and general wellbeing were assessed on a
horizontal visual analogue scale ranging from 0 to 100 mm, with 0 representing the
best score (no problems) and 100 representing the worst score. Swelling and
tenderness were assessed with the 28-joint score.7,8 Grip strength was measured in
kPa with a vigorimeter (range, 0 to 200 kPa); the mean of three measurements was
calculated for each hand. Disability was assessed with a validated Dutch version of
the Health Assessment Questionnaire (Vragenlijst Dagelijks Functioneren),9 which
had a range of 0 to 3 (0 represented the best score [no problems], and 3 represented
the worst score). Serum C-reactive protein level was measured in mg/L. To investigate
the possible sparing effect of the trial medication, we recorded the use of NSAIDs
and analgesics, the frequency of intra-articular corticosteroid injections, and the
use of physiotherapy. The patients recorded the use of NSAIDs, analgesics, and
physical therapy in standardized patient diaries. To calculate the use of NSAIDs
and to compare different NSAIDs, we arbitrarily chose naproxen as a reference.
One thousand mg of naproxen was defined as 1 unit and was considered to be
approximately equivalent to 600 mg of azapropazone, 100 mg of diclofenac, 200
mg of flurbiprofen, 1600 mg of ibuprofen, 100 mg of indomethacin, 200 mg of
ketoprofen, 15 mg of meloxicam, 1000 mg of nabumetone, 20 mg of piroxicam,
and 600 mg of tiaprofenic acid. Every 3 months, the first author recorded use of
intra-articular corticosteroid injections.
Radiologic outcome measures were erosions, joint space narrowing, and the
total score for both (range, 0 to 448). The total score is the sum of the erosions
and narrowing scores in 44 joints in the hands and feet, assessed on plain radiography
and scored with the van der Heijde modification of the Sharp method.10,11 Radiologic
outcome measures also included the number of patients with erosive disease in
each group and the number of radiologically affected joints per patient.
Radiographs were taken at entry and every 6 months. An assistant prepared the
radiographs to be read, and all identifying patient data on the radiographs were
concealed from the readers. The readers had no knowledge of patient identity
when they scored the radiographs. Radiographs were read in random patient order
and were scored for each patient in temporal order. Scoring in temporal order
clearly has advantages, as a comparative study has shown.11 However, with this
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method, scores can either be stable or increase; a decrease (indicating improvement)
is not possible. The first author and an independent radiologist viewed all available
radiographs at one center. When the readers’ total scores for individual cases
differed by 25% or more, agreement was reached through discussion. Joint damage
was defined as a score that exceeded 0. To correct for possible differences between
the two treatment groups in the number of patients who developed little or no joint
damage, we also analyzed data only from patients who developed joint damage.
Furthermore, radiologic damage was also analyzed with a cutoff point of 4 modified
Sharp units. A score of 0 to 3 was interpreted as no damage, and scores of 4 or
greater were interpreted as joint damage. This cutoff point seems to reflect clinically
relevant change12 and was also used in our study to define erosive rheumatoid
arthritis.
At the start of the study and every 3 months for 2 years, standardized lists were
used to document adverse effects. We noted the occurrence of infections and the
use of antibiotics; the latter was checked at the patient’s pharmacy. For hypertension,
the first author used a single device to measure blood pressure in mm Hg. For
steroid diabetes, serum glucose level was measured in mmol/L. Hyperglycemia
was defined according to the World Health Organization standard: postprandial, a
glucose level of at least 11.0 mmol/L (198 mg/dL), and fasting, at least 6.6 mmol/L
(119 mg/dL). Urinary glucose level was measured by using a semiquantitative method
(dipstick). A value less than 2.7 mmol/L (49 mg/dL) was considered negative, a
value of 2.7 to 5.5 mmol/L (50 to 99 mg/dL) was considered a trace, a value of 5.6
to 16.6 mmol/L (100 to 299 mg/dL) was considered 1+, a value of 16.7 to 54.9
mmol/L (300 to 989 mg/dL) was considered 2+, and a value of 55 mmol/L or greater
(≥ 990 mg/dL) was considered 3+. To assess weight gain, body weight in kg was
determined with a standardized scale. Gastrointestinal bleeding, ulcers, and peptic
symptoms were documented, and the decision to perform gastroscopy was made
clinically. Skin disorders were documented, and additional dermatologic expertise
was requested when necessary. Hemogram and laboratory variables for kidney
and liver function were assessed to monitor for hematologic and biochemical
abnormalities. For eye disorders, symptoms and abnormalities were documented;
when necessary, additional ophthalmologic expertise was requested. Neuropsycho-
logical disorders were recorded.
To assess for osteoporosis, we obtained a radiograph of the spine at baseline
and every 6 months for 24 months. We examined vertebrae Th12 through L5. The
first author and an independent rheumatologist scored the vertebrae blind, according
to the method of Kleerekoper.13 This method is based on naked-eye inspection of
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the vertebrae and comparison of each vertebra with the vertebrae below and above.
If an abnormal shape is noticed, the anterior, middle, and posterior heights of that
particular vertebra are measured with a ruler. The mean of the heights measured by
the two authors was used. The scoring system is as follows: 0 (normal shape and
dimensions), 1 (only endplate deformity, middle height, < 85%), 2 (anterior wedge
deformity, anterior height, < 85%), and 3 (compression deformity, all 3 heights, <
85%).13
Statistical Analysis
All statistical analyses evaluating the effect of treatment were performed according
to the intention-to-treat principle. For the 10 patients who withdrew during the
study, the outcomes of the last measurements were carried forward, with the
exception of the radiologic scores. For radiologic scores, missing data were
estimated by using individual progression, as indicated by available scores; if the
last measurements had been carried forward, the protective effect of medication
on the joints would have been overestimated. Also, “on treatment” analyses were
performed to validate the procedures used to estimate the missing data. For
radiologic joint damage, which is in itself a cumulative score, and the secondary
outcome measures (disability and grip strength), mean differences in changes from
baseline between the two groups were tested at 24 months with two-sided t-tests
or the Mann–Whitney U-test, where appropriate. For the other outcome measures,
changes from baseline over time (24 months) were compared by using the change
from baseline in the area under the curve (AUC) as a summary measure. This was
done because baseline variables between the two groups favored the prednisone
group, although the differences were not statistically significant (Table 1).14 We
divided the values for the change in AUC by the number of assessments at follow-
up. Since the interval between assessments is identical (3 months), this makes the
values for the change in AUC identical to the mean value of the changes occurring
in each 3-months interval at follow-up. Therefore, the values for changes in AUC
are easily interpretable.
The values for the change in AUC in both groups and the means of radiologic
scores for each group at different points in time were tested for statistically significant
differences by using unpaired two-sided t-tests or Mann–Whitney U-tests, where
appropriate. We calculated the number of patients in each group who had clinically
relevant improvement. Clinically relevant improvement was defined as at least 20%
improvement in the 28-joint scores for swelling and tenderness and at least 20%
improvement in at least two of the four following variables: pain, general wellbeing,
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Health Assessment Questionnaire score, and C-reactive protein level. In repeated-
measurement analyses of variance, the clinical outcome measurements were used
to analyze the relationship between time (disease course) and the effect of the
medication (prednisone) on the clinical status of the patient. This allowed us to
determine whether patients in the prednisone group showed improvement sooner
than patients in the placebo group. To determine whether outcome measurements,
patients’ characteristics, side effects, and additional therapies statistically significantly
differed between groups, we used unpaired, two-sided t-tests or Mann–Whitney
U-tests, where appropriate, for the means and Fisher exact tests for proportions.
Changes from baseline within groups were tested with paired t-tests or Wilcoxon
signed-rank tests, where appropriate. All analyses were performed with the Number
Cruncher Statistical System 97 (NCSS Statistical Software, Kaysville, Utah).
RESULTS
Thirty-seven of 118 patients declined to participate in the study for the following
reasons: a wish to become pregnant, concern about the side effects of glucocorti-
coids, the inconvenience of visits to the hospital outpatient department and frequent
monitoring, and unwillingness to take the 50% risk for receiving placebo. Patients
who declined to participate had a mean age (±SD)of 48 ± 12 years. Twenty-five
were women, 28 had IgM rheumatoid factor, and 14 had erosive changes on
radiographs of the hands or feet. Compared with study participants, patients who
declined participation were younger and more likely to be women. Patient
characteristics at the start of the study are shown in Table 1. No statistically
significant differences were seen between the two groups. All patients were white
except for 2 patients in the prednisone group.
Ten patients withdrew from the study, 4 in the prednisone group and 6 in the
placebo group (Figure 1). Patients in the prednisone group withdrew because of
emigration (1 patient at 15 months), loss of motivation (1 patient at 12 months),
alcohol abuse (1 patient at 21 months), and death from myocardial infarction (1
patient at 21 months). Patients in the placebo group withdrew because of cervix
carcinoma (1 patient lost to follow-up at 12 months), ischemic cerebrovascular
accidents that were attributed to arteriosclerosis (1 patient at 6 months and 1 patient
at 9 months), loss of motivation (1 patient at 9 months), and rheumatoid arthritis
vasculitis (1 patient who died at 3 months and 1 patient who died at 6 months
despite aggressive immunosuppressive therapy). Of the 10 patients who withdrew,
1 patient in the prednisone group (alcohol abuse) and 1 in the placebo group (loss
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of motivation) received sulfasalazine as rescue medication at 15 and 6 months,
respectively. No patients left the study because of adverse effects related to the
study medication. After 6 months, 39 of the 71 patients who completed the study
(20 in the placebo group and 19 in the prednisone group) received sulfasalazine as
additional antirheumatic therapy.
TABLE 1
Baseline Characteristics of the 81 Patients with Early Rheumatoid Arthritis*
Characteristic Prednisone Group( n = 40) Placebo Group( n = 41)
Age, y 60 ± 14 64 ± 12
Male/female, n/n 17 / 23 12 / 29
IgM rheumatoid factor, n† 29 31
Erosive disease, n‡ 16  15
Early-morning stiffness, min 100  ±  62  117  ±  71
Morning pain, mm§ 28 ± 20 34 ± 25
General wellbeing, mm§ 31 ± 23 41 ± 23
28-Joint score for swelling 7.3 ± 3.7 8.6 ± 4.3
28-Joint score for tenderness 8.9 ± 5.7 8.6 ± 5.0
Grip strength, kPa 49 ± 24 47 ± 24
Disability score £ 0.8 ± 0.6 1.0 ± 0.7
C-reactive protein level, mg/L 11 ± 18 20 ± 28
Radiologic score for hands and feet¶ 11 ± 11 15 ± 21
Hypertension, n** 5 11
Chronic obstructive pulmonary disease, n 1 2
History of documented peptic ulcer, n 1 (> 10 years ago)  0
Peptic symptoms treated with medication, n 4 1
Cardiovascular disease, n 1 (coronary bypass)  0
* Values presented with a plus/minus sign are the mean ± SD. No statistically significant differences were seen
between groups.
† Rheumatoid factor status was considered positive when the IgM rheumatoid factor level was ≥ 25 IU/mL. This
cutoff point yielded a false-positive test result for < 5% of the general population.
‡ A Sharp–van der Heijde erosion score of ≥ 4 was considered erosive, and a score of 0 to 3 was considered
nonerosive.
§ Measured with the visual analogue scale. Morning pain and general wellbeing in the previous 48 hours were
calculated on a scale from 0 to 100 mm, with 0 representing the best score (no problems) and 100 representing the
worst score.
£ Measured with a Dutch version of the Health Assessment Questionnaire.9 Scores ranged from 0 to 3, with 0
representing the best score (no problems) and 3 representing the worst score.
¶ Erosions and joint space narrowing were assessed by using the van der Heijde modification of the Sharp method.10,11
Scores ranged from 0 (no damage) to 448 (maximum score for erosions and joint space narrowing in hands and feet).
** These patients were normotensive with medication at the start of the study.
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TABLE 2
Effects of Prednisone Treatment in Patients with Early Rheumatoid Arthritis*
Variable Prednisone Placebo 95% CI P Value
 Group Group for the
( n = 40) ( n = 41) Difference
Changes from baseline
12 months
Radiologic damage 8 ± 13 15 ± 15 0.008
Grip strength, kPA 13 ± 21 -1 ± 19 5 to 23 0.002
Functional disability† 0.1 ± 0.6 0.1 ± 0.6 > 0.2
24 months
Radiologic damage 16 ± 23 29 ± 26 0.007
Grip strength, kPA 13 ± 19 4 ± 24 0 to 19 0.05
Functional disability† 0.1 ± 0.7 0.0 ± 0.6 > 0.2
Change in AUC at 24 months‡
Early-morning stiffness, min -43 ± 69 -28 ± 78 > 0.2
Morning pain, mm§ -5 ± 17 1 ± 22 -2 to 15 0.14
General wellbeing, mm§ -1 ± 24 0 ± 18 > 0.2
28-Joint score for swelling -2 ± 4 -1 ± 4 -1 to 2 > 0.2
28-Joint score for tenderness -2 ± 4 0 ± 5 1 to 5 0.01
C-reactive protein level, g/L -1 ± 15 0 ± 24 > 0.2
Individual patient improvement, n/n (%)£
At 12 months 13/40 (33) 10/41 (24) -0.1 to 0.3 > 0.2
At 24 months 12/40 (30) 9/41 (22) -0.1 to 0.3 > 0.2
Cumulative use of additional therapy
Patients receiving physiotherapy, n/n
At 6 months 7/40 12/41 -0.3 to 0.1 >0.2
At 24 months 12/40 19/41 -0.4 to 0.0 0.17
Physiotherapy sessions, n
At 6 months 108 308
At 24 months 701 771
Patients receiving intra-articular
corticosteroid injections, n/n¶
At 6 months 2/40 11/41 -0.4 to -0.1 0.01
At 24 months 8/40 12/41 -0.3 to 0.1 > 0.2
Injections, n
At 6 months 2 21
At 24 months 17 43
Patients taking paracetamol, n/n**
At 6 months 23/40 23/41 -0.2 to 0.2 > 0.2
At 24 months 25/40 24/41 -0.2 to 0.3 > 0.2
Paracetamol tablets, n
At 6 months 772 2546
At 24 months 4237 8334
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Clinical Efficacy
For most clinical variables, the changes from base-line favored the prednisone
group at 12 and 24 months but did not differ significantly between the two groups.
Exceptions were grip strength and the 28-joint score for tenderness; for these
variables, a larger, statistically significant improvement was seen in the prednisone
group compared with the placebo group (Table 2). A statistically significant
interaction of time and medication was seen for three clinical variables: pain, 28-
joint score for tenderness, and grip strength. Plots of these variables in time showed
that this was due to more rapid improvement during the first 6 months in the
prednisone group than in the placebo group (data not shown). Individual patient
improvement was 33% in the prednisone group and 24% in the placebo group at
12 months and 30% and 22%, respectively, at 24 months (Table 2).
Overall use of physiotherapy was significantly lower in the prednisone group
than in the placebo group, especially in the first 6 months. At 24 months, the
difference in the total number of sessions of physiotherapy was not as pronounced
but continued to favor the prednisone group. In the first 6 months, 2 intra-articular
corticosteroid injections were administered in the prednisone group and 21 were
administered in the placebo group. The total number of intra-articular injections
given in the prednisone group at 24 months was 40% lower than that in the placebo
group. A total of 772 paracetamol tablets were taken in the first 6 months in the
prednisone group compared with 2546 in the placebo group. At 24 months, use of
paracetamol in the prednisone group was 49% lower than that in the placebo group.
The overall use of NSAIDs over 24 months was also considerably lower in the
prednisone group than in the placebo group (Figure 2).
* Values presented with a plus/minus sign are the mean ± SD. Unpaired two-sided t-tests were used for normal
distribution of the data, and Mann–Whitney U-tests were used for non-normal distribution; in the latter cases, no
95% CIs for the difference are given. AUC = area under the curve.
† Measured with a Dutch version of the Health Assessment Questionnaire. Scores ranged from 0 to 3, with 0
representing the best score (no problems) and 3 representing the worst score.9
‡ The values for the change in AUC were divided by the number of assessments at follow-up, making them identical
(since the interval between assessments [3 months] is identical) to the mean value of the changes occurring in each
3-month interval at follow-up. This was done to simplify interpretation of the data.
§ Measured with the visual analogue scale. Morning pain and general wellbeing in the previous 48 hours were
assessed on a scale of 0 to 100 mm, with 0 representing the best score (no problems) and 100 representing the worst
score.
£ Improvement is defined as ≥ 20% improvement in the 28-joint score for swelling and the 28-joint score for tenderness
and ≥ 20% improvement in ≥ 2 of the 4 following variables: visual analogue scale score for pain, visual analogue scale
score for general wellbeing, disability score, and C-reactive protein level.
¶ A corticosteroid injection was defined as 40 mg of triamcinolone acetonide or equivalent.
** The use of nonsteroidal anti-inflammatory drugs is reported in Figure 2. Two patients in each group used
additional analgesics (pentazocine, 50 mg; tramadol, 50 mg; or dextropropoxyphene, 150 mg).
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Disease-Modifying Properties
Fifty patients (24 in the prednisone group [60%] and 26 in the placebo group
[63%]) had nonerosive disease at the start of the study. At 24 months, 30% of
patients in the prednisone group and 22% in the prednisone group still had nonerosive
disease. At baseline, the mean total score for radiologic outcome measures (the
combination of the scores for joint space narrowing and erosions) was slightly
higher for the placebo group than for the prednisone group, although the difference
was not statistically significant (Table 1). From month 12 on, radiologic scores
showed significantly less progression in the prednisone group than in the placebo
group. Mean changes (±SD) from baseline in modified Sharp scores were 8 ± 13
and 15 ± 15 at 12 months for the prednisone and placebo groups, respectively
(P = 0.008; effect size, 0.52) and 16 ± 23 and 29 ± 26, respectively, at 24 months
(P = 0.007; effect size, 0.56) (Table 2).
Radiologic scores over time are shown in Figure 3. At 12 months, the total
mean score (±SD) for radiologic damage was 19 ± 19 for the prednisone group
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Figure 2. Cumulative mean use of nonsteroidal anti-inflammatory drugs ( NSAIDs) in units.
One unit = 1000 mg of naproxen or the equivalent dose of another NSAID. At follow-up at all points
in time, statistically significant differences were seen between the two groups (P < 0.001 [Mann–
Whitney U-test]). The solid line indicates the prednisone group; the dotted line indicates the placebo
group. Error bars represent the standard error.
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Figure 3. All scores are means and are based on the van der Heijde modication of the Sharp method.10, 11
Solid lines indicate the prednisone group; dotted lines indicate the placebo group. Error bars represent
the standarderror. * P = 0.04; † P = 0.02.
Time, mo
To
ta
l S
co
re
Time, mo
Er
os
io
n 
Sc
or
e
Time, mo
Na
rro
wi
ng
 S
co
re
0
5
10
15
20
25
30
35
40
45
50
0 6 12 18 24
0
5
10
15
20
25
30
35
40
45
50
0 6 12 18 24
0
5
10
15
20
0 6 12 18 24
*
*
†
†
*
*
CHAPTER 2
30
TABLE 3
Adverse Effects and Complications
Adverse Effect or Complication Events in the Events in the
Prednisone Group Placebo Group
 ( n = 40)  ( n = 41)
Infections treated with antibiotics, n/n*
Skin 0 5 (4 patients)
Respiratory tract 13 (11 patients) 13 (9 patients)
Intestinal tract† 1 2
Urinary tract 3 (2 patients) 2
Gastrointestinal
Stomatitis‡ 0 1
Nausea/vomiting 2 2
Peptic symptoms leading to gastroscopy 7 3
Ulcer with bleeding on gastroscopy 1 2
Diarrhea 0 2
Cardiovascular
Newly developed hypertension 7 6
Angina pectoris 3 3
Myocardial infarction§ 1 0
Ischemic cerebrovascular accident £ 0 2
Arterial occlusion in legs 0 1
Calf vein thrombosis 0 2
Heart rhythm disorders 1 2
Congestive heart failure 1 1
Ankle edema 1 0
Skin (excluding infections)
Ulcus cruris 3 2
Exanthema 2 1
Petechiae 1 1
Ophthalmologic
Glaucoma 1 0
Cataract 1 1
Vitreous humor hemorrhage¶ 1 0
New osteoporotic fractures**
Vertebral 7 (5 patients) 4 (2 patients)
Peripheral (pelvis) 1 0
Miscellaneous
Impotence†† 0 2
Depression 1 2
Concentration disorders 0 1
Cervix carcinoma‡‡ 0 1
Medication-dependent diabetes mellitus 2 1
Systemic vasculitis§§ 0 2
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and 30 ± 28 for the placebo group (P = 0.04). At 24 months, the scores were 27 ±
28 and 44 ± 37, respectively (P = 0.02) (Figure 3, top). The mean score for
erosions at 12 months was 11 ± 13 in the prednisone group and 19 ± 23 in the
placebo group (P = 0.08). At 24 months, the scores were 16 ± 20 compared with
29 ± 30, respectively (P = 0.04) (Figure 3, middle). The mean scores for joint
space narrowing were 9 ± 9 in the prednisone group and 11 ± 9 in the placebo
group at 12 months (P = 0.06) and 11 ± 10 and 15 ± 10, respectively, at 24 months
(P = 0.02) (Figure 3, bottom). The mean total numbers of affected joints per
patient in the prednisone group and the placebo group were 10 ± 7 and 13 ± 8 at 12
months (P = 0.05) and 12 ± 9 and 16 ± 9 at 24 months (P = 0.047), respectively.
Similar differences in all radiologic scores between the two groups were found by
“on treatment” analyses (n = 71), analyses only of patients de-veloping joint damage,
and analyses of radiologic damage with a cutoff point of 4 (0 to 3, no damage; ≥ 4,
joint damage) (data not shown).
Adverse Effects
We compared body weight, serum glucose levels, and blood pressure at the start
of the study and after 24 months of treatment. In the prednisone group, the mean
body weight (±SD) increased significantly from baseline, from 77 ± 19 kg to 80 ±
20 kg (P = 0.001). In the placebo group, no statistically significant change was
seen. Also in contrast to the placebo group, the mean serum glucose level (±SD)
increased significantly in the prednisone group, from 5.1 ± 0.6 mmol/L to 5.9 ± 1.9
mmol/L (92 ± 11 mg/dL to 106 ± 34 mg/ dL) (P = 0.01). Hyperglycemia, as
defined by the World Health Organization, developed in 2 patients in the prednisone
group and 1 in the placebo group. The other variables did not change significantly
in either group. At the start of the study, 1 patient in each group had one vertebral
* The number of infections not treated with antibiotics, such as the common cold, was similar in both groups.
† No cultures were taken.
‡ Stomatitis was caused by allergy, probably to a nonsteroidal anti-inflammatory drug used, according to the
patient’s dermatologist.
§ Cause of death. The patient was 76 years of age.
£ Cause of withdrawal from the study. The patients were 72 and 73 years of age.
¶ Probably not related to the study medication.
** Vertebral fractures Th12 to L5, assessed according to the Kleerekoper method.13 At the start of the study, one
patient in each group had a vertebral fracture.
†† Impotence was not included in the standardized diary but was spontaneously reported by these two patients.
‡‡ Cause of withdrawal from the study.
§§ Cause of death. The patients were 62 and 78 years of age.
CHAPTER 2
32
fracture (from Th12 to L5). After 24 months, the number of new vertebral fractures
was higher in the prednisone group than in the placebo group. Five patients in the
prednisone group had new fractures in the spine; of these 5 patients, 3 had a single
fracture and 2 had two fractures. The patient in the prednisone group with a fracture
at baseline did not develop new fractures. In the placebo group, 2 patients had new
vertebral fractures. One was the patient with a fracture at baseline who developed
another fracture; the other patient developed three fractures. Except for one
osteoporotic fracture of the pelvis in the prednisone group, no osteoporotic fractures
outside the spine (forearms, ribs, pelvis, or hips) were seen (Table 3).
Other adverse effects are shown in Table 3. There were minor infections in
both groups. Patients in the prednisone group had no serious skin infections, but
erysipelas was seen five times in 4 patients in the placebo group. The numbers of
infections in the respiratory, gastrointestinal, and urinary tracts were approximately
equal in the two groups. Three patients (1 in the prednisone group and 2 in the
placebo group) developed peptic ulcer disease with bleeding, which was confirmed
by gastroscopy. The numbers of patients with newly developed hypertension during
the study were approximately equal (7 in the prednisone group and 6 in the placebo
group). At the start of the study, 11 patients in the placebo group and 5 in the
prednisone group were normotensive because of medication for essential
hypertension, and they remained stable during the study. In the prednisone group,
1 patient (76 years of age) died after 21 months of a myocardial infarction (confirmed
at autopsy). During the study, 3 patients (2 in the prednisone group and 1 in the
placebo group) developed diabetes mellitus, which was managed with oral
antidiabetic agents and diet; no insulin treatment was needed. Except for infections,
the two groups had an equal number of adverse effects affecting the skin, which
were well controlled with conservative treatment. Serum aminotransferase levels
were elevated in 1 patient in the prednisone group and 1 in the placebo group;
values were less than two times the upper limit of normal. Mean serum creatinine
concentration did not increase during the study in either group. No other biochemical
or hematologic abnormalities were seen during the study. One patient in the
prednisone group had glaucoma that was well controlled with conservative treatment,
and 1 patient in each group had a cataract. One patient in the prednisone group had
a hemorrhage in the vitreous humor in the right eye that caused partial loss of
vision, but this complication was probably unrelated to the study medication. No
disorders of the central nervous system were observed. For patients with newly
developed depressive symptoms (1 in the prednisone group and 2 in the placebo
group), no medication was needed.
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DISCUSSION
The Medical Research Council and Nuffield Foundation trials in the mid-1950s
and mid-1960s suggested a possible disease-modifying role for glucocorticoids. It
is difficult to interpret the results of these trials, however, because of the heterogeneity
of the patient groups, the long duration of disease at the start of the studies,
confounding by indication, and multiple concomitant therapies. In 1995, in a double-
blind, placebo-controlled study of 128 patients with early rheumatoid arthritis
(average disease duration, 1.3 years), Kirwan demonstrated a significant reduction
in progression of radiologic joint damage in the hands when glucocorticoids were
added to antirheumatic treatment.15 Patients received prednisone (7.5 mg/d) or
placebo for 2 years in addition to NSAIDs (95% of patients) and disease-modifying
antirheumatic drugs (71% of patients).
After 2 years, both the total number of new erosions and the number of patients
with erosions were significantly lower in the glucocorticoid group. Clinical variables
improved only during the first year of therapy. Kirwan concluded that a fixed daily
dose of 7.5 mg of prednisone given as adjuvant therapy for early active rheumatoid
arthritis retards radiologic progression of joint destruction. However, only hands
were evaluated for the radiologic score. In a 1998 follow-up study by Hickling and
coworkers,16 joint destruction resumed after the prednisone dosage was tapered
and therapy was discontinued.
In 1996, Saag and associates17 reviewed the literature systematically and
performed a meta-analysis of the effectiveness of low-dose glucocorticoids in
rheumatoid arthritis. Glucocorticoids seemed to be at least as effective as other
therapies in improving disease activity. However, data were limited because the
treatment episodes were relatively short (7 months on average) and glucocorticoids
were given late in the disease course, often in combination with disease-modifying
antirheumatic drugs.
In a randomized study of early rheumatoid arthritis, Boers and colleagues18
compared the effect of sulfasalazine monotherapy with that of combined therapy
with prednisone, methotrexate, and sulfasalazine. Prednisone was started at an
initial dosage of 60 mg/d, which was tapered in six steps over 6 weeks to 7.5 mg/d,
and was withdrawn at week 28. The combined therapeutic regimen slowed radiologic
damage significantly more than sulfasalazine alone at weeks 28, 56, and 80. Haagsma
and coworkers13 and Dougados and associates19, however, found no differences
in effect between sulfasalazine and the combination of sulfasalazine and methotrexate
in patients with rheumatoid arthritis. Therefore, the difference in effectiveness
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between combination therapy and sulfasalazine in the study by Boers and colleagues
was probably due to the effect of prednisone. In addition, the combined therapy
offered better disease control. In contrast to our present study, the cohort of
patients with rheumatoid arthritis in the study by Boers and colleagues was younger
and had more active disease. Patients received prednisone at an initial dosage of 60
mg/d, which was tapered; treatment was stopped at 28 weeks. During that 1-year
study, the effect of combination therapy on progression of joint destruction persisted
after 28 weeks but clinical remission ended in most patients.
Our study is unique because it did not include concomitant therapy with disease-
modifying antirheumatic drugs at study entry. We were therefore able to assess the
effects of steroids on joint damage independent of disease-modifying antirheumatic
drugs. In our study, most patients taking low-dose prednisone needed less additional
therapy and showed temporary improvement in most disease variables when
compared with the placebo group, although the differences were not statistically
significant for all variables. This may be due to more intensive use of additional
therapies, including NSAIDs, in the control group (Table 2 and Figure 2). The
clinical improvement seen in the studies by Kirwan15 and by Boers and colleagues18
lasted longer, for more than 6 months but less than 1 year, at which point the
treatment groups no longer differed from the control groups. Compared with
prednisone as monotherapy, combination of glucocorticoids with disease-modifying
antirheumatic drugs or biological agents in early active rheumatoid arthritis might
prolong the clinical benefit. The remarkable retardation of radiologically detected
joint destruction in our study was similar to that observed in the studies by Kirwan15
and by Boers and colleagues.18 The difference between the two groups in our
study even increased gradually until the end of the second year. We do not advocate
use of glucocorticoids as monotherapy, however. In our opinion, glucocorticoids,
because of their limited disease-modifying effects, should be combined with disease-
modifying antirheumatic drugs in patients with rheumatoid arthritis.
In our study, glucocorticoid-induced osteoporosis was a major side effect. We
prescribed calcium supplementation for all patients, but if we were performing this
study today, we would use more intensive treatment, such as bisphosphonates.
This would probably result in fewer signs and symptoms of osteoporosis.
Glucocorticoids suppress a wide variety of nonspecific inflammatory responses
(such as cell trafficking and prostaglandin production), as well as specific immune
processes, with emphasis on cytokine modulation. At a cellular level, glucocorticoids
inhibit the access of leukocytes to inflammatory sites; modulate the functions of
leukocytes, endothelial cells, and fibroblasts; inhibit the production and functioning
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of a variety of pro-inflammatory cytokines while enhancing the production of anti-
inflammatory mediators; and suppress the synthesis of cartilage-degrading
metalloproteases by fibroblasts and articular chondrocytes. Taken together, these
effects induce the marked clinical amelioration of rheumatoid arthritis21 and may
also explain the protection of bone and cartilage against inflammation-induced
degradation, which in turn may explain the drugs’ disease-modifying properties.
In conclusion, low-dose prednisone alleviates symptoms of rheumatoid arthritis
and has disease-modifying properties. Further investigation of long-term low-dose
glucocorticoid therapy in rheumatoid arthritis that examines not only symptoms
but especially joint damage and functional outcome is needed.
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Abstract
To investigate the incidence of osteoporotic fractures and effects on bone of low-
dose glucocorticoid (GC) in a group of previously untreated patients with early
active RA we performed a double blind, randomised, placebo-controlled clinical
trial. The study duration was 2 years, with an open follow-up during the third year.
Patients were randomly allocated to receive 10 mg prednisone or placebo.
Non-steroidal anti-inflammatory drugs (NSAIDs) were allowed in both groups.
After 6 months sulphasalazine (2 gr daily) could be prescribed as rescue therapy in
both groups. Except for 500 mg calcium supplement daily, no specific preventive
measures were taken.
At the start of the study and every 6 months, X-rays of the twelfth thoracic and
of all lumbar vertebrae were scored using the Kleerekoper method, and every year
biochemical parameters of bone metabolism and bone mineral density (BMD) were
assessed.
In the prednisone group there was a higher incidence during the study of lumbar
vertebral fractures than in the placebo group: 7 vs 4 respectively. This difference
did not reach statistical significance however, probably because of the small
numbers. One patient of the prednisone group suffered an osteoporotic fracture of
the pelvis. In the 2-year study and the subsequent follow-up year, no other peripheral
fractures were seen in either group. No significant changes from baseline in BMD
of the hips and lumbar spine were seen in either group during the study and the
follow-up year: BMD values in both groups did not differ significantly during the
whole study. No correlation between changes in serum osteocalcin and BMD was
observed.
Low-dose prednisone for patients with early active previously untreated RA
seems also  to increase the risk of fractures independent of the BMD.
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INTRODUCTION
In rheumatoid arthritis (RA) periarticular as well as generalised bone loss is an early
feature of the disease with an increased risk of fractures of 1.5 to 2.1.1-3 Bone
formation is normal or reduced and bone resorption is increased in RA patients
compared to healthy controls. Bone loss is the result of this uncoupling between
bone formation and resorption. The aetiology of generalised bone loss in RA is
multifactorial. Inflammation with circulating cytokines and hypogonadism as well
as general factors such as decreased physical and weight-bearing activity, age,
vitamin D status, hormonal status and physical impairment play a role.4,5
Another risk factor for osteoporosis is treatment with glucocorticoids (GC); in
general this therapy doubles the risk of fractures.6 However there is still debate as
to whether low-dose GC treatment of an active inflammatory disease also results in
the development of osteoporosis and an increased risk of fractures. In contrast to
the negative effects on bone, low-dose GC treatment of patients with RA reduces
disease activity and joint damage and enhances mobility, effects that are anti-
osteoporotic.7 Therefore, the positive effects of low-dose GC treatment of patients
with RA on disease activity and joint damage may counterbalance the negative
effects on bone.3,6,7 In various studies the incidence of clinical manifestations of
vertebral fractures was significantly higher in patients with RA treated with GC
compared to RA patients without GC.8,9 However, interpretation of the results of
other studies is difficult because of confounding factors such as the administration
of prednisone only to patients with more active disease (allocation bias).
The aim of our study, in which prednisone therapy was randomly allocated
(thus excluding allocation bias for prednisone) was to investigate the effects on
bone and the risk of fractures of low-dose prednisone in patients with early active
previously untreated RA.
PATIENTS AND METHODS
Patients
From October 1992 through October 1995 eighty-one out of 118 eligible
consecutive outpatients of the Departments of Rheumatology of the Deventer and
Zutphen Hospitals, who were at least 18 years of age, had early previously untreated
RA (disease duration less than one year), and satisfied the 1986 ARA-classification,
were enrolled in the study.10 Inclusion criteria were: active disease defined as (at
least 2 out of 3): 28 joint score for tenderness and 28 joint score for swelling of 3
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or more, Westergren erythrocyte sedimentation rate (ESR) 28 mm after one hour
or higher and early morning stiffness lasting 30 minutes or longer.11-12 Exclusion
criteria were contraindications for the use of prednisone and/or NSAID’s, serious
concomitant diseases, active gastrointestinal problems, severe hypertension,
haemorrhagic diathesis, treatment with cytotoxic or immunosuppressive drugs,
alcohol or drug abuse and severe psychiatric or mental problems.
Informed consent was obtained from all subjects prior to participation. Of the
118 eligible patients, thirty-seven refused to participate.
Intervention
The 81 participating patients were randomly allocated in blocs of 10 subjects by
the Pharmacy of the Deventer Hospital to one of two groups for treatment for two
years: 1) two tablets of 5 mg prednisone once daily at breakfast (=10 mg), 2)
placebo tablets in the same way. The Pharmacology Department prepared and
labelled the prednisone and placebo tablets, which were identical in shape, taste
and colour. Both groups of patients received 500 mg elementary calcium in the
evening to retard GC-induced osteoporosis as was the normal procedure at that
time (study designed in 1989-91). According to current knowledge patients would
now be treated with bisphosphonates and/or vitamin D and 1000 mg elementary
calcium.
The code of randomisation was broken after 2 years of treatment. Dosage was
then tapered off for patients receiving prednisone. At every visit the surplus tablets
of the study medication were counted; compliance was satisfactory (96%). Use of
NSAID’s was free. Local CS injections were permitted only if unavoidable. Physical
therapy and additional use of paracetamol were allowed and recorded every 3
months. After 6 months sulphasalazine (2 gr. daily) could be prescribed as rescue
medication. The decision to add sulphazalazine was based on clinical grounds
only (activity of RA).
Design, setting
This prospective, double-blind, randomised, placebo-controlled trial was approved
by the Ethics Committees of the University Medical Center Utrecht and the Deventer
and Zutphen Hospitals. At the time the study was designed (1989-91), the study
design was considered ethically acceptable; later it became clear that irreversible
joint damage in RA is an early feature of the disease. With our present knowledge
comparison of the effects of prednisone and placebo in patients who did not
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TABLE 1
Baseline characteristics of the 81 patients with early RA (number of patients (n) or means and standard
deviations). There were no statistically significant differences between the two groups.
Characteristic Prednisone Group( n = 40) Placebo Group( n = 41)
Age in years 60 ( 14 ) 64 ( 12 )
Male/female (n) 17 / 23 12 / 29
IgM rheumatoid factor positive ‡ (n patients) 29 31
Patients with erosive disease (n) 16 15
28 Joint score for swelling 7 ( 4 ) 9 ( 4 )
28 Joint score for tenderness 9 ( 6 ) 9 ( 5 )
Vas pain in mm¶ 11 ( 18 ) 20 ( 28 )
HAQ* 0.8 ( 0.6 ) 1.0 ( 0.7 )
CRP in mg/L 28 ( 20 ) 34 ( 25 )
Serum creatinine in umol/l# 81 ( 15 ) 80 ( 12 )
Serum 25-OH vitamin D@ 72 ( 35 ) 61 ( 21 )
‡ RF status was considered positive when the IgM-RF was 25 IU/ml or more, a cut-off point resulting in a false-
positive test for less than 5% of the general population.
¶ VAS (visual analogue scale) for morning pain and general wellbeing referred to the previous 48 hours on a scale
ranging from 0 -100 mm, 0 representing the best (no problems) and 100 the worst score.
* A Dutch version of the HAQ (VDF, Vragenlijst Dagelijks Functioneren), its score ranging from 0-3, 0 representing
the best (no problems) and 3 the worst score.26
# Serum creatinine: normal  ≤ 110 male; ≤ 90 female.
@ Normal range: 25-150 nmol/L; only one patient (in the prednisone group) had a subnormal value (23 nmol/L).
receive a DMARD for at least six months would probably be considered unethical.
In our study sulphasalazine as rescue medication could be prescribed only after 6
months in order not to obscure the effects of prednisone monotherapy.
Measurements
At the start of the study and every 3 months for three years, variables on disease
activity and adverse effects were assessed: the results are reported elsewhere.7 In
this report, baseline values of joint scores, visual analogue scale (VAS) pain (0-100
mm), the HAQ score and serum C-reactive protein are shown in Table 1.
At the start of the study and every 6 months radiographs of the lower thoracic
and lumbar spine were made and assessed according to the method of Kleerekoper.13
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The vertebrae (Th 12 through L 5) were scored by naked eye inspection and
compared to the vertebrae below and above by two observers (AAvE, DH). The
radiographs were prepared for reading by a houseman; data of the patients on the
radiographs were blinded from the observers. The observers had no knowledge of
the identity of the patients on the radiographs at the time of scoring. Radiographs
were read in random patient order and scored for each patient in temporal order:
0 (normal shape and dimensions), 1 (only endplate deformity, middle height <
85%), 2 (anterior wedge deformity, anterior height < 85%) and 3 (compression
deformity, all heights < 85%). The maximum score was 18.
At the start of the study and once every year bone mineral density (BMD) of
the lumbar spine (L2-4) and collum femoris of both hips was measured by dual-
energy X-ray absorptiometry (BMD in g/cm2) (Hologic QDR-4500A) with a cut-
off point for changes from baseline >0.27 g/cm2. BMD values were expressed as
T-scores and changes from baseline. Osteocalcin in serum (mg/L; measured by
OStK-Pr radioimmunoassay kit purchased from CIS BIO International, GIP-SUR-
Yvette, Cedex France) and excretion of hydroxyproline in 24-hour samples of
urine (um/24h/m2) on a hydroxyproline-poor diet, considered at the time of the
study the most reliable markers of bone metabolism, were measured in addition to
excretion of calcium and creatinine in 24h urine in mmol/24h.
At the start of the study and every 3 months serum creatinine in umol/L was
assessed and at the start of the study also serum 25-OH vitamin D.
Statistical analysis
All statistical analyses to evaluate possible effects of treatment on bone were
performed with patients ‘on treatment ’; ‘intention to treat ’ analysis with estimation
of missing data by carrying the last measurement forward would have yielded  a
too positive result. For the 10 patients in the 2-year study and the 6 patients in the
follow-up year who dropped out, the outcomes of clinical variables were estimated
conservatively according to the method of last measurements carried forward.
Outcome measurements were tested for statistically significant differences between
the two groups using unpaired, two-sided T-tests or Mann-Whitney U tests, where
appropriate, for the means and Fishers’exact test for proportions.
Correlations were calculated between osteocalcin and BMD and between CRP
and BMD using Pearson’s correlation coefficients.
All analyses were performed with the statistical package “Number Cruncher
Statistical System” version 97 (Jerry Hintze, Kaysville, Utah).
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TABLE 2
Bone mineral densities (T-scores) and fractures across time for patients with RA (prednisone vs. placebo)
Time in months, means (standard error of the mean, SEM), number of patients
Time in months 0 12 24 36
T-score Lumbar spine
-prednisone (n = 32) -0.8 (0.3) -1.0 (0.3) -1.1 (0.3) -1.1 (0.3)
-placebo (n = 33) -0.7 (0.3) -0.6 (0.3) -0.6 (0.3) -0.6 (0.3)
T-score Femoral neck
-prednisone (n = 32) -1.8 (0.2) -1.8 (0.2) -1.9 (0.2) -1.8 (0.2)
-placebo (n = 33) -1.9 (0.2) -1.9 (0.2) -1.9 (0.2) -1.9 (0.2)
Cumulative number of Fractures
-prednisone 1 5 8 10
-placebo 1 2 5 5
Cumulative number of patients with fractures
 (total number of patients)
-prednisone 1 (40) 4 (40) 5 (36) 5 (31)
-placebo 1 (41) 2 (36) 2 (35) 2 (33)
RESULTS
Patients’ characteristics at the start of the study are shown in Table 1: there were
no statistically significant differences between groups. All patients were Caucasian
except for two in the prednisone group: one Asian and one Mediterranean. Of the
118 patients 37 declined to participate in the study. They had the following
characteristics: mean age 48 (SD 12) years; 25 were female; 28 patients had IgM-
rheumatoid factor and 14 exhibited erosive changes on radiographs of the hands
and/or feet. So, the group of non-participants consisted of relatively more female
and younger patients compared to the study group.
Ten patients dropped out of the study: 4 in the prednisone group and 6 in the
placebo group, details are described elsewhere.7 For 65 of the 71 patients all BMD
measurements were available. No significant changes from baseline in BMD of the
hips and lumbar spine were seen in either group nor significant differences between
both groups, see Table 2.
At the start of the study there was one patient in each group with one vertebral
fracture (Th12-L5). After 24 months, 5 patients in the prednisone group had new
fractures in the lumbar spine: 3 patients had a single fracture and 2 had 2 fractures.
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The one patient who had a fracture at the start did not develop new fractures. In the
placebo group 1 patient had 3 new vertebral fractures and the one patient who had
had a fracture at the start of the study had developed a new one. Except for one
osteoporotic fracture of the pelvis, no other fractures (forearms, ribs or hip) were
seen (Table 2). During the follow-up year no new vertebral fractures occurred in
the placebo group. In the prednisone group 2 patients who already had vertebral
fractures developed a new vertebral fracture.
The first patient entered the 2-year study in 1993; the last patient finished the
study in 1998. In 1999 we were able to take radiographs of the thoracic and lumbar
spine of 59 out of the 65 patients. There were no new fractures in the placebo
group. In the prednisone group there was one thoracic vertebral fracture in a patient
who was known to have a lumbar vertebral fracture: 2 patients who had had lumbar
vertebral fractures had both developed one new lumbar fracture.
At the start of the study, only one patient (in the prednisone group) had a
subnormal 25-OH vitamin D level: 23 (normal: 25-150 nmol/L).
There was a significantly lower serum osteocalcin level at 12 and 24 months in
the prednisone group compared to the placebo group (p-value 0.05 and 0.007,
respectively). There was also a significantly higher calcium excretion in samples of
24h urine at 24 months in the prednisone group (p-value 0.0008). No statistically
significant differences were found for the excretion of hydroxyproline in samples
of 24h urine.
No statistically significant correlations were found between serum osteocalcin
and BMD and between serum CRP and BMD (data not shown).
DISCUSSION
In our 2-year placebo-controlled (and 1-year follow-up) study, which showed joint
protective properties of low-dose prednisone for patients with early previously
untreated active RA, we found more vertebral fractures in the prednisone group
compared to the placebo group but this (clinically relevant) difference did not
reach statistical significance, probably because of the small numbers. No clinically
relevant nor statistically significant differences in BMD measurements were found
between the group of patients treated with prednisone and the group on placebo.
There was a higher disease activity in the placebo group compared to the prednisone
group but no clear differences in clinical variables, probably because the use of
NSAID’s was more than doubled in the placebo group compared to the placebo
group to the prednisone group (details reported elsewhere).7 In inflammatory
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diseases such as RA, there is a positive correlation between disease activity, bone
turnover and rate of fractures, most of which are vertebral deformities.6 Probably
in our study the negative effect of disease activity on bone that was higher in the
placebo group counterbalanced the negative effect of prednisone in the prednisone
group: hence no statistically difference between the two groups regarding BMD.
In recent literature the relationship between low-dose GC treatment, the
development of low BMD and the risk of fractures is a subject of controversy.
Most of these retrospective studies were performed with patients with longstanding
RA and the results are controversial.8,14 We will go into these studies in short.
In several studies on low-dose long-term GC treatment of postmenopausal RA
patients, a higher incidence of fractures -especially of the vertebrae and femoral
neck- compared to RA patients who did not receive GC and had a lower BMD
was reported.9,15
In a cohort of patients with a variety of diseases no difference was found in the
relationship between changes in BMD and vertebral fractures between patients
receiving GC and who were not on this therapy.16 In contrast, in other studies
higher fracture rates than could be expected from the observed changes in BMD
were reported,17,18 as in our study. However, there is a difference between the
study population for those studies and our patients, all of whom had previously
untreated, active early RA. The fact that our study, which was free of allocation
bias, was indicative of a discrepancy between bone strength and BMD in patients
on prednisone, seems to confirm the hypothesis that GC treatment may lead to
fractures also via effects on bone other than a decrease in BMD, i.e. changes in
bone strength and structure.19 For patients with a variety of diseases who are on
long-standing GC treatment, the risk of fractures can be explained for only 40% by
the value of BMD, the other 60% by other factors such as the risk of falling (5).
At the time of our study it was standard procedure only to provide a supplement of
500 mg elementary calcium daily for patients with RA treated with GC to prevent
osteoporosis. After 1996 a number of well-conducted studies was published
showing the efficacy of bisphosphonates in combination with calcium and vitamin D
in preventing bone loss and even increasing BMD in patients treated with GC.20-23
Nowadays it is considered unethical to perform studies with GC without adequate
prevention of osteoporosis.
Statistically significant differences were found between the two groups in serum
osteocalcin levels and excretion of calcium in 24h samples of urine: lower serum
osteocalcin and higher calcium excretion characterised the prednisone group. No
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correlations were found in either group between bone markers, disease activity and
the BMD. Our finding of a statistically significant decrease in serum osteocalcin
and the excretion of calcium in 24h urine for the prednisone group compared to the
placebo group contrasts with data in the literature. In a study of postmenopausal
women with longstanding RA no significant differences in biochemical markers of
bone turnover were observed between RA patients treated with low-dose GC and
those receiving placebo.15 Another study did not find significant differences in
excretion of calcium in 24h urine.24 In a similar study there were no differences in
serum osteocalcin between the prednisone and placebo groups.25 Differences with
respect to our study of early RA patients could possibly be explained by a different
disease duration: the majority of other studies were performed with patients with
longstanding RA.
At this time only one study on the effects of short-term low-dose GC on bone
metabolism in patients with active RA has been published.8
The hypothesis that the positive effects of GC on disease activity might
counterbalance the negative effects on bone might explain the lack of correlation
between disease activity (CRP) and bone marker (osteocalcin in serum).
In conclusion, in our study without allocation bias for prednisone, a discrepancy
seems to be present between the lack of change in BMD and the increased albeit
not statistically significant incidence of fractures in patients with early active RA
treated with low-dose prednisone. Apparently mechanisms other than a decreased
BMD are also responsible for diminished bone strength and an increased risk of
fractures.
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Abstract
Objective
In our former analysis in patients with early active rheumatoid arthritis (RA), treated
with 10 mg prednisone or placebo discrepancies between both groups were found.
In contrast to a significant retardation of joint damage in the prednisone group
compared to the placebo group, there were no differences in clinical variables
between the 2 groups, attributable to more use of additional therapy in the placebo
group than in the placebo group.
Aim of the study: to investigate whether this discrepancy, regarding different
dimensions of RA, would extend to variables of wellbeing.
Methods
A double blind, randomized, placebo-controlled clinical trial, duration 2 years (10
mg prednisone or placebo), including an open follow-up third year of 81 patients
with early (≤ 1 year) active previously untreated RA. Forty-one patients were allocated
to 10 mg prednisone orally daily and 40 to placebo. Analgesics, NSAIDs, restricted
use of local steroid injections and use of physiotherapy were allowed in both
groups. After 6 months sulphasalazine (2 gr daily) could be prescribed as “rescue”
therapy in both groups. At start and every 6 months thereafter 2 health status
questionnaires VDF (Dutch version of the HAQ) and IRGL (Dutch version of the
AIMS) were administered and every 3 months a visual analogue scale (VAS) for
morning pain. Furthermore, disease activity and radiological scores were assessed.
Results
Scores of the VDF showed no statistically significant differences between the
prednisone group and the placebo group. No statistical differences were found in
almost all parameters of the IRGL between groups. At 3 months the VAS morning
pain and the VAS general wellbeing showed improvement in the prednisone group
comparable with the transient improvement in some other disease activity variables.
In the prednisone group the cumulative use of NSAIDs, analgesics, local steroid
injections and sessions of physiotherapy was about 50% of that of the placebo
group.
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Conclusion
Although significant retardation of joint damage in the prednisone group indicates
better disease control, no differences between both groups were found for variables
of wellbeing. This discrepancy can probably be attributed to increased use of
additional therapy in the placebo group. So, the use of additional therapies should
thus be taken into account in analyzing and interpreting results of clinical drug
trials.
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INTRODUCTION
In daily clinical practice with patients with rheumatoid arthritis (RA), most physicians
assume a direct association between disease activity, general wellbeing and joint
damage late in the course of the disease. Therapeutic approaches of patients with
RA are based on these assumptions. Frequently, in the treatment of these patients,
in addition to disease modifying antirheumatic drugs (DMARDs),
glucocorticosteroids (GC) are used for instantaneous relieve of symptoms and for
improvement of general wellbeing. Recently, several studies on RA suggest also
disease-modifying properties of long-term low-dose GC.1- 5 These studies describe
effects on disease activity and joint damage whereas few studies describe the effects
on wellbeing 6. In most of these studies the use of additional therapies such as
analgesics, NSAIDs, local injections and physiotherapy are not taken into account.
In healthy adult volunteers and non-RA patients the effects of GC on cognitive
functioning and psychological side effects have extensively been described and
reviewed.7- 8 In our analysis of patients with early active previously untreated RA,
we saw no enduring differences in variables of disease activity and physical
functioning between the prednisone 10 mg group and the placebo group.1 In the
prednisone group however, better disease control was achieved, as significant
retardation of joint damage occurred, compared the placebo group. This discrepancy
between radiological and clinical effects could be attributed to the greater amount
of analgesics and NSAIDs used in the latter group.  It thus makes a difference
whether suppression of signs and symptoms is achieved with low dose prednisone
or extra analgesics and NSAIDs. This difference might extend to variables of
wellbeing. From daily practice, low-dose prednisone could be hypothesized to
have more effects on wellbeing than extra analgesics and NSAIDs.
There are more data suggesting that disease activity and wellbeing are not always
well balanced or strictly coupled in the course of RA. Androgens as adjuvant
treatment led to improvement in general wellbeing of postmenopausal women with
active RA but not in disease activity.9 In a study comparing the use of alternative or
complementary therapy (CM) with conventional therapy of patients with RA, a
higher impact of RA in the absence of worse disease was perceived by users of
CM in several domains of life, especially psychological functioning.10
The aim of the present study is to investigate whether the discrepancy found in
our analysis between disease activity variables and joint damage also extends to
variables of wellbeing and to investigate the role of additional therapies in interpreting
results of clinical drug trials.
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PATIENTS AND METHODS
Patients
From October 1992 through October 1995, eighty-one out of 118 eligible
consecutive outpatients, who were at least18 years of age, with early previously
untreated RA (disease duration less than one year), according the 1986 ARA-
classification, were enclosed in the study.1 The patients were recruited from the
Departments of Rheumatology of the Deventer and Zutphen Hospitals, the
Netherlands, and randomly allocated in blocs of 10 subjects to one of two groups
of treatment for two years: 1) two tablets of 5 mg prednisone once daily at breakfast
(=10 mg), 2) placebo in the same way. Use of NSAIDs, physical therapy and
paracetamol was free of choice. Restricted use of local GC injections was allowed.
After 6 months sulphasalazine (2 gr. daily) could be prescribed as additive “rescue”
medication. The decision to add sulphasalazine was based on clinical grounds
(activity of RA).
Variables
At start and every 6 months thereafter, two validated health status questionnaires
were administered:
1) VDF: functional disability assessed with a validated Dutch version of the Health
Assessment Questionnaire. The VDF contains of 20 items, which are grouped
into 8 scales representing dressing, arising, eating, walking, hygiene, reach, grip
and outside activity. Patients are asked about the ability to perform activities
without help, with responses ‘able to do without difficulty ‘(score 0), ‘able to
do with some difficulty ‘(score 1), ‘able to do with much difficulty’ (score 2)
and ‘unable to do’ (score 3). Furthermore, patients are asked whether or not
they use a cane, a wheelchair, an adapted bed or chair, or devices for dressing,
hygiene, or eating and whether or not they are assisted in performing any of the
activities of the 8 scales. The total VDF score may vary from 0-3, 0 representing
the best (no problems) and 3 the worst score.11
2) IRGL: Impact of Rheumatic diseases on General health and Lifestyle. The IRGL
is a health status questionnaire, developed from the Arthritis Impact Measurement
Scales 1 (AIMS 1) assessing physical, psychological and social functioning as
well as the impact of the disease on daily life.12 The scales of the IRGL differ in
their individual ranges and are expressed in the original direction: for example,
high values on the scale pain and low values on the scale mobility and self care
indicate a poor health status. The IRGL has been validated in the Netherlands.13
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The IRGL assesses the various domains of health as follows:
· Physical wellbeing: 21 items: 7 for the scale mobility, 8 for the scale self care
and 6 for the scale pain
· Psychological wellbeing: 22 items: 6 for the scale depressive mood, 6 for the
scale cheerful mood and 10 for the scale anxiety
· Social wellbeing: 13 items: 2 for quantitative aspects of the scale of social
support and 11 for qualitative aspects forming 3 scales: potential exchange of
emotional support, actual exchange of emotional support and mutual visits
· Arthritis Impact: 12 items of the impact of RA on daily life: work, housekeeping,
hobbies, holidays, leisure, sexuality, eating and sleeping habits, relationships
with the partner, family and friends and family life
We also assessed every 3 months a visual analogue scale (VAS) for early morning
pain and one for general wellbeing regarding the past week, both scales ranging
from 0 to 100 mm, 0 representing the best and 100 the worst score.
From start and every 3 months thereafter the number of NSAIDs, analgesics, physical
therapy and local intraarticular injections was assessed.
As parameters for disease activity were assessed C- reactive protein (CRP),
early morning stiffness recorded in minutes, the 28 joint score for tenderness and
the 28 joint score for swelling and grip strength. At start and every 6 months
thereafter, radiographs of hand and feet were performed and scored according to
the Sharp/van der Heijde method.1, 14- 16
Statistical analysis
All statistical analyses to evaluate the effect of treatment were performed according
to the ‘intention to treat ‘principle. For the 10 patients who dropped out during the
study, outcomes of the last measurements were carried forward, with the exception
of the radiological scores. For radiological scores, missing data were estimated
using individual progression as indicated by available scores; last measurements
carried forward would have been too positive as estimation, suggesting no further
deterioration. For the VDF, IRGL, the VAS morning pain, the VAS general wellbeing,
CRP, early morning stiffness, the 28 joint score for swelling and the 28 joint score
for pain, mean differences in changes from baseline between the two groups were
tested at 24 months with two-sided T-tests or the Mann-Whitney U-test, where
appropriate (see Table 1).
Baseline variables and patients’ characteristics were tested for statistically
significant differences between the two groups using unpaired, two-sided T-tests
or Mann-Whitney U tests, where appropriate, for means and with Fishers’ exact
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tests for proportions). Individual patient improvement was assessed according to
the modified 20% ACR improvement criteria: details are described in our earlier
report.1
All analyses were performed with the statistical package “Number Cruncher
Statistical System” version 97 (Jerry Hintze, Kaysville, Utah).
RESULTS
Patient characteristics, VDF, VAS early morning pain, VAS general wellbeing and 3
domains of the IRGL at the start of the study are shown in Table 1: there were no
statistically significant differences between the two groups. All patients were
Caucasian except for two in the prednisone group.
TABLE 1
Baseline characteristics of the 81 patients with early RA γ  (numbers, means and standard deviations)
Prednisone  n = 40 Placebo  n = 41
Age in years 60 ( 14 ) 64 ( 12 )
Male/female (n) 17 / 23 12 / 29
IgM rheumatoid factor positive ‡ (n patients) 29 31
Patients with erosive disease (n) # 16 15
Variables of wellbeing
- Disability score ( VDF )* 0.8 ( 0.6 ) 1.0 ( 0.7 )
- IRGL mobilityº 21.6 ( 6 ) 19.2 ( 6 )
- IRGL self careº 25.6 ( 5 ) 25.6 ( 5 )
- IRGL painº 14.9 ( 4 ) 16.7 ( 4 )
- VAS morning pain³ 28 ( 20 ) 34 ( 25 )
- VAS general wellbeing ¶ 31 ( 23 ) 41 ( 23 )
γ no statistically significant differences between the two groups
‡ RF status was considered positive when the IgM-RF was 25 IU/ml or more, a cut-off point resulting in a false-
positive test for less than 5% of the general population.
* VDF (Vragenlijst Dagelijks Functioneren) is a Dutch version of the HAQ questionnaire, its score ranging from 0-3,
0 representing the best (no problems) and 3 the worst score 11.
# Sharp-van der Heijde erosion score of ≥ 4 was considered to be erosive and
0-3 non-erosive 6.
° IRGL Impact of Rheumatic diseases on General health and Lifestyle; mobility, range 7-28, 7 representing the worst
score and 28 the best score; self care, range 8-32, 7 representing the worst score and 28 the best score; pain, range
6-25, 6 representing the worst score and 25 the best score 12.
³ Visual analogue scale (VAS) of morning pain 0-100 mm., 0 the best score, 100 the worst score
¶ Visual analogue scale (VAS) of general wellbeing 0-100mm, 0 the best score, 100 the worst score
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Ten patients discontinued the study: 4 in the prednisone group and 6 in the placebo
group.1 No patient discontinued the two-year study for reasons of adverse events
of the study medication in either group. After 6 months 39 out of the 71 patients
who completed this study received suphasalazine as additional antirheumatic therapy
on clinical grounds: 20 in the placebo and 19 in the prednisone group.
The use of analgesics and NSAIDs in the prednisone group was about 50% of
that of the placebo group as was also the case for the number of local steroid
injections and sessions of physiotherapy.1
Wellbeing variables (Table 2; Figure 1-5)
Scores of the VDF showed no statistically significant differences (see Figure 1).
In the items of the scales of the IRGL at 6, 12 and 24 months statistically significant
differences between the groups were seen for depressed mood and potential support
in favor of the prednisone group; no differences were seen in the other items of the
scales (see Table 2; Figure 2,3). There were statistically significant differences at
3 months in the VAS early morning pain and the VAS general wellbeing between
the prednisone group and the placebo group in favor of the prednisone group (see
Figure 4,5).
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Figure 1. The VDF (a Dutch version of the HAQ) of patients with early RA treated with prednisone
compared to placebo (means, SEM). There were no statistically significant differences between both
groups VDF (Vragenlijst Dagelijks Functioneren) is a Dutch version of the HAQ questionnaire, its
score ranging from 0-3, 0 representing the best (no problems) and 3 the worst score.11
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Disease activity variables
In our study, patients of the prednisone group showed improvement in 8 clinical
parameters in the first 3 months compared to the placebo group. The clinical
improvement in the prednisone group was transient: after 6 months the only clinical
variables showing statistically significant differences were the 28 joint score for
tenderness and the grip strength. Most of the clinical variables exhibited no statistically
significant differences from baseline between the two groups although the actual
improvement was slightly in favor of the prednisone group, reaching statistical
significance for the 28 joint score for tenderness (p=0.01). Grip strength improved
significantly and consistently in the prednisone group 1. Thirty-three percent of
TABLE 2
Effect of treatment on IRGL scales of patients with early RA; the prednisone group (pred) versus the
placebo group (plac) (means, sem, p-value
at baseline at 24 months
range pred sem plac sem p pred sem Plac sem p
Mobility   8-32 21.6 0.6 21.4 0.6 0.09 20.9 0.6 21.5 0.6 0.2
Self care   8-32 25.6 0.5 25.6 0.5 1.0 28.2 0.7 27.0 0.6 0.6
Pain   6-25 14.9 0.4 16.7 0.4 0.09 12.1 0.6 13.5 0.6 0.8
Depressed mood   0-24   3.2 0.5   4.7 0.4 0.02**   3.3 0.4   3.1 0.4 0.06
Cheerful mood okt-24 10.9 0.5 10.3 0.6 0.5 11.0 0.5 11.6 0.5 0.2
Anxiety   5-20 19.0 0.5 19.6 0.6 0.7 17.9 0.6 17.6 0.5 0.7
Potential support   5-20 14.7 0.4 14.9 0.4 0.9 16.0 0.4 15.5 0.4 0.004**
Actual support 00-xx   6.7 0.2  6.6 0.2 0.8   6.5 0.2   6.8 0.2 1.0
Number of friends   2-8   7.1 0.5 12.4 0.6 0.01**   5.0 0.4   8.1 0.4 0.2
Exchange of visitors   1-4   6.0 0.2   6.0 0.1 0.2   3.0 0.2   3.4 0.2 0.3
Impact on activities   1-4   9.6 0.4 11.4 0.4 0.1   8.5 0.4   9.0 0.4 1.0
Impact on sexuality   1-4   1.6 0.1  1.6 0.1 0.9   3.8 0.2   3.0 0.2 0.2
Impact on eating and   2-8   2.9 0.2   3.4 0.2 0.2   2.9 0.2   3.4 0.2 1.0
sleeping
Impact on nutrition/sleep   2-8   2.8 0.2   3.1 0.1 0.4   2.6 0.2   2.7 0.2 0.7
Impact on ADL   1-4 16.8 0.6 19.0 0.6 0.1 15.4 0.6 16.8 0.7 0.7
Impact on relationship   1-4 11.7 0.1 15.0 0.1 0.5   1.8 0.8   2.0 0.1 0.2
partner
Impact on family life   1-4   1.5 0.1   1.5 0.1 1.0   6.7 0.5   2.1 0.1 0.4
*p=<0.05 between groups. At 6 months also statistically significant differences between both groups for poten-
tial support p=0.03 and at 18 months for depressed mood p= 0.03; data not shown.
**p=<0.05
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Figure 2. The IRGL scale, potential support of patients with early RA treated with prednisone
compared to placebo (means, SEM).
p = 0.05 at 6 months, 0.04 at 12 and 0.004 at 24 month
IRGL Impact of Rheumatic diseases on General health and Lifestyle; mobility, range 7-28, 7 representing
the worst score and 28 the best score; self care, range 8-32, 7 representing the worst score and 28 the
best score; pain, range 6-25, 6 representing the worst score and 25 the best score.12
Figure 3. The IRGL scale, depressed mood of patients with early RA treated with prednisone
compared to placebo (means, SEM).
p = 0.02 at start and 0.03 at 18 months
IRGL Impact of Rheumatic diseases on General health and Lifestyle; mobility, range 7-28, 7 representing
the worst score and 28 the best score; self care, range 8-32, 7 representing the worst score and 28 the
best score; pain, range 6-25, 6 representing the worst score and 25 the best score.12
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Figure 4. VAS (visual analogue scale) morning pain of patients with early RA treated with prednisone
compared to placebo (means, SEM).
p = 0.0003 at 3 months
Visual analogue scale (VAS) of morning pain 0-100 mm., 0 the best score, 100 the worst score.
Figure 5. VAS (visual analogue scale) general wellbeing of patients with early RA treated with
prednisone compared to placebo (means, SEM).
p = 0.003 at 3 and 0.04 at 6 months
Visual analogue scale (VAS) of general wellbeing 0-100mm, 0 the best score, 100 the worst score.
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patients in the prednisone group satisfied the modified 20% ACR individual patient
improvement criteria and 24% of patients did in the placebo group at 12 months
and 30% and 22%, respectively, at 24 months.
Joint damage
At the start of the study there was no statistically significant difference in joint
damage in the prednisone group compared to the placebo group. After one and
two years there were statistically significant differences between both groups in
favor of the prednisone group,1 increasing in time.
DISCUSSION
In our study with long term low-dose GC treatment in patients with early active
previously untreated RA compared to placebo we found a transient amelioration
of disease activity but a significant ongoing reduction in joint damage.1
The aim of this study was to investigate general wellbeing in these patients and
the role of additional therapies in evaluating the effects of the different treatment
strategies. In daily practice GC lead to immediate relief of clinical symptoms and
improvement of general wellbeing in patients with RA but relatively little is known
about the long term effects on parameters of wellbeing.17 In the long term, functional
disability of patients with RA will be affected not only by current inflammatory
activity but also by structural joint damage.18 In a study comparing disease activity,
joint destruction and functional capacity over the course of RA, functional capacity
appears to be associated with disease activity in early RA and with joint damage in
late disease.19 In a reappraisal of HAQ-disability in RA as a function of disease
over time, the HAQ may be an inadequate model due to the patient’s upward
reappraisal of functional ability with increasing time.20
Over time, we found no enduring differences between the groups for most
variables. Scores of the VDF (Dutch version of the HAQ) showed some
improvement in the prednisone group, but no statistically significant differences
(Figure 1). In the domains of the IRGL, 3 items were statistically significantly
different in favor of the prednisone group at some points of time (Figure 2,3).
There was a transient improvement in the VAS early morning pain as well as in the
VAS general wellbeing  (Figure 4,5).
Little is known about the use and effects of additional therapies such as
analgesics, NSAIDs, local injections and physiotherapy on aspects of general
wellbeing in studies of different therapy strategies in patients with RA. In the present
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study the cumulative use of these  additional therapies in the prednisone group was
50 % of that in the placebo group. In another study of patients with RA on the
effectiveness of early treatment with DMARDs also a doubling of intra-articular
injections was found in the first year in the non-DMARD versus the DMARD
group (44% vs. 22%).17 In spite of better disease control, reflected by significant
inhibition of joint damage in the prednisone group vs. the placebo group, no
difference in wellbeing variables was found, probably due to higher use of additional
therapy in the placebo group. The same result was found for clinical disease activity
variables.
Therefore, in future clinical drug trials, the use of additional therapies should
thus be taken into account analyzing clinical differences in effect; clinical and
wellbeing variables not always accurately reflect disease control.
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Abstract
Objective
In patients with rheumatoid arthritis (RA) of longer duration, glucocorticoid receptor
(GR) down-regulation has been reported, without change in cortisol levels. This
phenomenon might play a role in the aetio-pathogenesis of RA. Therefore we
studied the GR-expression, as well as the serum cortisol levels in patients with
recently diagnosed RA.
Methods
In 81 early diagnosed RA patients with disease duration < 1 year (52F/29M; mean
(SD) age 63(13) years) and in 39 age and sex matched controls (23F/16M;mean
age 63(15) years) blood samples were taken between 8-10h AM. GR-expression
(GR-number and GR-affinity), serum cortisol levels, ESR, CRP, painful and swollen
joints were measured.
Results
A significantly lower GR-number was found in the female patients compared with
female controls: 7.0 versus 9.8 fmol/million cells, respectively (difference: 2.8,
95% CI 1.1 – 4.6). Interestingly, also serum cortisol levels were significantly lower
in the female patients compared with the female controls: 0.21 versus 0.41 µmol/l,
respectively (difference: 0.20, 95% CI 0.12 – 0.28). However, between the male
patients and male controls, no difference was found, in GR-expression nor in
serum cortisol levels. Neither in female nor in male patients correlations were found
of GR-expression with parameters of disease activity nor was there a relation between
GR-expression and serum cortisol levels.
Conclusion
Changes in GR-expression as well as serum cortisol were not a general phenomenon
in early diagnosed RA patients, being only present in females and not related to
disease activity. Therefore it seems unlikely that GR-expression per se is causally
involved in the pathogenesis of RA. We cannot preclude that it may be involved in
the incidence, severity and course of RA, as this may be differentially regulated in
males and females.
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INTRODUCTION
Glucocorticoids are being successfully used in the treatment of early rheumatoid
arthritis (RA) because of their potent anti-inflammatory action. Not all patients do
respond however and if so, some patients respond to low doses, while others
require larger doses for seemingly identical clinical situations. Glucocorticoids exert
their effects through the glucocorticoid receptor (GR) located in the cytoplasm of
target cells at low doses,1,2 but at higher doses genomic (i.e. through the GR) as
well as non-genomic modes of action play a role.3 It is known that the number of
intracellular GRs per cell is closely related to the biological response upon
glucocorticoid exposure to that cell.4 In this context the GR expression of peripheral
mononuclear cells (PBMC) is considered to reflect in vivo biological effects of
glucocorticoids in healthy persons and in a variety of disorders.5-9 GR in normal
leukocytes do not show significant alterations within a day, in contrast to plasma
cortisol levels.5 GR down regulation might hinder the effectiveness of the immune-
hypothalamic- pituitary-adrenal axis in the control of inflammation and therefore
might play a role in the aetio-pathogenesis of RA.6,10
Schlaghecke et al. showed a diminished GR-number per cell in mononuclear
leukocytes of RA patients with active disease of longer duration (mean 6 years)
compared with healthy controls.6,11 There were no differences in GR binding affinity
or serum cortisol levels. No correlation was found between GR-number and age or
sex, RA activity or serum cortisol. The decrease in GR-number in RA is compatible
with impaired activity of the hypothalamic-pituitary-adrenal (HPA) axis.10,12,13 The
diminished receptor density in RA patients did not result in glucocorticoid resistance
in the sense that proliferation and cytokine release (interleukine 1 and 6) of
lymphocytes of RA patients and healthy controls were inhibited by glucocorticoids
to the same extent.11 This study was done with relatively high glucocorticoid doses:
adding glucocorticoids to PBMC, acting by GR, but probably also by the
qualitatively quite different non-genomic (i.e. not GR related) effects of
glucocorticoids.3 In contrast to the diminished GRs in active RA patients, Sanden
et al. showed in patients with rheumatic diseases an overall increase in the number
of GRs compared with healthy controls. However, patients in this study had a
variety of different rheumatic diseases with a large range in disease activity. The
increased number of GRs decreased on glucocorticoid therapy in a dose-dependent
way.14
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If GR-downregulation plays a role in the aetio-pathogenesis of RA a diminished
GR-number would not only be found in RA of longer duration,6 but especially in
early-diagnosed RA. To investigate this hypothesis, we compared the GR-expression
as well as the serumcortisol levels of early RA-patients with those of age-and sex-
matched healthy controls.
PATIENTS AND METHODS
Patients
Eighty-one consecutive outpatients with recently diagnosed (early) RA (disease
duration < 1 year) were included. All patients fulfilled the ACR criteria and were
DMARD and glucocorticoid naive. 68% of the RA patients (55 out of 81) used
non steroidal anti-inflammatory drugs (NSAID’s) and 74% (60 out of 81) were
IgMRF positive. Age varied between 24 and 82 years with a mean (SD) age of
63(13) years. The cohort consisted of 29 males (age 61(12) years) and 52 females
(age 64(13)). From these patients disease activity (ESR, CRP, number of tender
and swollen joints) and serum cortisol levels were determined.  From the last 50
included patients glucocorticoid receptor (GR) density and affinity were determined
as well. This sub-population had a similar mean age (64(12) years) and age distribution
(varying from 29 to 82 years) as the entire group. Also the male / female ratio (19 /
31), and age distribution between both sexes (male 63(13); female 65(12)) were
similar to the entire group. In addition, cortisol, GR-density and -affinity were
determined from an age and sex matched group of healthy individuals. This group
included 39 individuals with a mean age of 63(15) years: 16 males (61(12) years)
and 23 females (62(16) years).
Assays
Swollen and tender joints were scored as has been described.15 Blood samples
were collected between 8:00 and 10:00 AM. Erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) were determined according to standard procedures.
Serum cortisol levels were determined using a fluorescence polarisation immuno-
assay (FPIA; Abbot, Illinois, USA) according to manufacturer instructions. The
inter-assay coefficients of variation were 4.6, 3.3 and 3.8% at serum concentrations
of 0.29, 0.47 and 0.81 µmol/l, respectively (n=54, 54 and 24).
GR density and affinity in PBMC were determined as follows: PBMC were
isolated from 40 ml (EDTA) blood using Ficoll-paque density centrifugation.16-19
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The cell suspension was stored overnight at 4°C in Iscove’s medium supplemented
with 10% foetal bovine serum that was absorbed with dextran-coated charcoal to
remove free steroid.20 PBMC were centrifugated and washed 2 times with Hanks
balanced salt solution HBSS (without calcium or magnesium; with 3.6 mM NaHCO3,
pH7.2, 4°C). Trypan blue staining revealed ≥95% viable cells. A binding curve was
made in duplicate by adding 100 µl 3H-dexamethasone in 7 concentrations  (1.25-
40 nM Amersham; 3.18 TBq/mmol) to 1-2 x106 cells per 100 µl. At the end of the
incubation period (at 24°C with rotation for 90 min), cells were washed 3 times
with 20 mM sodium molybdate dihydrate in HBSS to stabilise receptor-ligand
binding,21 followed by quantification of the bound 3H-dexamethasone using
scintillation analysis. The maximum 3H-dexamethasone binding based on scatchard
analysis22,23 revealed the number of unoccupied GRs expressed in fmol/million
cells, recalculated in absolute number of receptors per cell. The slope of the line in
scatchard analysis reflects the GR binding affinity (Kd) expressed in nM.
Statistical evaluation
For comparison between groups, unpaired two-sided student’s T-tests or Mann-
Whitney U tests were used, where appropriate. In addition, multiple regression
analysis was done. Correlations, Spearman or Pearson coefficients, where
appropriate, were calculated between the different parameters. Statistical significance
was defined at P < 0.05. Data are expressed as mean ± SEM.
RESULTS
First the results are described of the whole group (Figures 1a, 1b and 1c) and
then those of women and men separately (Figures 2a, 2b and 2c). Figure 1a
shows the serum cortisol levels of the RA patients compared with healthy controls.
In this recently diagnosed RA population a statistically significantly lower serum
cortisol level was found compared to the controls (35% lower, p≤0.001). Multiple
regression analysis showed that age was not responsible for the difference in serum
cortisol levels between the RA cohort and the healthy controls. GR receptor numbers
(Figure 1b) were also statistically significantly lower (on average almost 20 %,
p<0.02) in these early RA patients compared with the controls. Again, age was not
responsible for this difference. Mean GR-affinity was slightly lower in the early RA
patients compared with the age and sex matched control group but no statistically
significant difference was obtained (Figure 1c).
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Figure 1a. Serum cortisol levels (µmol/l) of the
healthy controls (open bars) compared with
early-RA patients (gray bars). Values total control
group 0.37(0.03). Values total early-RA group
0.24(0.015). Mean values (SEM).
Figure 1b. GR-number: fmol/million cells. The
open bars represent the healthy control group
and the gray bars the early-RA group. Values
total control group 9.48(0.66). Values total RA
group 7.73(0.41). Mean values (SEM).
Figure 1c. GR-affinity (Kd) expressed in nM.
The open bars represent the healthy control group
and the gray bars the early-RA group. Values
total control group 7.19(0.48). Values total RA
group 8.64(0.53). Mean values (SEM).
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Figure 2a. Serum cortisol levels (µmol/l) of the healthy female controls (open bars) compared with
female early-RA group (gray bars). Values female control group: 0.41(0.05) and female early-RA
group 0.21(0.02). Values male control group: 0.30(0.035) and male early-RA group 0.29(0.03). Mean
values (SEM).
Figure 2b. GR-number: fmol/million cells. The open bars represent the healthy control group and the
gray bars the early-RA group. Values female control group: 9.84(0.79) and female early-RA group:
7.03(0.47). Values male control group: 8.92(0.35) and male early-RA group 8.88(0.71). Mean values
(SEM).
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Serum cortisol levels, GR number and affinity did not correlate with age, neither in
the controls, nor in the early RA group. For patients and controls together there
was a positive correlation between GR number and receptor affinity (correlation
coefficient 0.45, p≤ 0.001). No correlations of the GR parameters with serum
cortisol were found.
With respect to parameters of disease activity in the RA group, there were no
correlations of serum cortisol, GR-number or GR-affinity with ESR (mean 31 ± 3
mm/1st hour), CRP (mean 16 ± 3 mg/L), swollen joints (mean number 8.0 ± 0.4) or
tender joints (mean number 8.7 ± 0.6).
Surprisingly, the differences between the RA patients and the healthy controls were
almost entirely determined by the female patients. Significantly lower serum cortisol
levels were found in the female patients compared with female controls (0.21 versus
0.41 µmol/l; difference 0,20, 95% CI 0.12 – 0.28) (Figure 2a). Between the male
patients and male controls serum cortisol levels were not different. The serum
cortisol levels in controls were higher (although not statistically significant) in females
than in the males, but female RA patients had a lower serum cortisol level than the
male patients (28% lower, p≤0.02).
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Figure 2c. GR-affinity (Kd) in nM. The open bars represent the healthy control group and the gray
bars the early-RA group. Values female control group 6.53(0.44) and female early-RA group: 8.02(0.57).
Values male control group: 8.18(0.29) and male early-RA group 9.64(1.02). Mean values (SEM).
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Similar observations were found for the GR number. The female patients determined
the difference between the RA patients and controls. A significantly lower GR-
number was found in the female patients compared with female controls (7.0 versus
9.8 fmol/million cells; difference 2.8, 95% CI 1.1 – 4.6) (Figure 2b). For males no
differences were found in GR number between early RA patients and controls.
The GR-number was not statistically different between male and female controls
but in RA females they were lower than in the RA males (21% lower, p≤0.03).
The GR affinity showed a negative trend for both sexes: the Kd being higher
means that the affinity is lower in the early RA patients compared with controls.
These differences were not statistically significant (Figures 1c and 2c).
DISCUSSION
In our group of early RA patients a significantly lower serum cortisol and GR
number was found in the patients compared with controls. These findings suggest
that glucocorticoid control of inflammation may be impaired in early RA patients.
This is in agreement with the studies of Schlaghecke (adult RA patients with longer
disease duration)6 and Andreae (children with autoimmune diseases, two thirds of
them suffering from juvenile idiopathic arthritis).24 The lower serum cortisol and
GR number could completely be attributed to the female patients, since no
differences were observed between the male patients and their controls. The GR-
affinity tended to be lower in the patients compared with controls (Figures 1c
and 2c). However, this was not statistically significant. No correlations were found
between GR-number and parameters of disease activity, nor was there a relation
between GR-number and serum-cortisol levels. However, disease activity
determined by ESR, CRP, painful and swollen joints was rather low, so it was less
likely to find correlations.
Different studies show different outcomes with respect to early morning cortisol
levels in RA.25-27 Neeck et al. show for active RA patients increased serum cortisol
levels and disappearance of cortisol circadian rhythm.25 Their RA patients had a
much higher disease activity than our early RA patients. In patients with recent
onset RA the dynamic cortisol responsiveness as reflected in the early morning
rise is not disturbed.27 The studies of Neeck and Dekkers are in contrast to the
results of the study of van den Brink28 and our study in which decreased morning
serum cortisol levels in postmenopausal RA patients are found, reflecting a relative
hypocortisolism. Above mentioned discrepancies might be attributed to differences
in disease activity and disease duration, but also to the time of blood sampling,
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which is ideal at the moment of awakening. Patients in our study first had to travel
at least an hour before blood could be sampled between 8 – 10 AM; immediate
saliva sampling after awakening by the patient him or herself would have been
better.
Another way to study the HPA-axis in RA might be with an overnight
dexamethasone suppression test with a dose as low as 0.25 mg dexamethasone
instead of 1 mg. In case of relative hypercortisolism in early RA, differences might
be observed in suppressibility of the HPA-axis with an adjusted dexamethasone
suppression test of 0.25 mg.29 One mg dexamethasone might be a too high dose to
allow the detection of subtle individual differences in sensitivity of the HPA-axis to
glucocorticoids.
In RA patients with a mean disease duration of six years, GR-downregulation
has been reported without change in serum cortisol levels and without correlations
between GR-number and age or sex, RA-activity or serum cortisol levels.6,11 In
our early female RA patients a decrease in GR number was found as well a decrease
in serum cortisol levels. This was not the case in the early diagnosed male RA
patients. The discrepancy with the studies of Schlaghecke might be due to the fact
that the populations differ in time of onset of disease, disease activity and time of
blood sampling after awakening.6,11 The sex difference found in our study, the GR-
downregulation and lower serum cortisol levels being present in the early diagnosed
female RA patients but not in the early diagnosed male RA patients might be
related to interactions of sex hormones and the HPA-axis.2,30,31 The majority of
patients suffering from RA are females, suggesting that the balance between
androgens and estrogens plays a role in susceptibility of RA.31,32 The depressive
effects of androgens on the immune system might protect males against RA.30,31 In
addition androgens are considered as adjuvant therapy for men and postmenopausal
women with RA, having anabolic and slightly disease modifying effects.33-36
Estrogens and androgens have been shown to affect the GR expression in the
central nervous system.30 Estrogens decrease the expression of GRs in the anterior
pituitary, hypothalamus and hippocampus of gonadectomized female rats, whereas
androgens have the opposite effect upon GR expression in the medial pre-optic
area of orchidectomized male rats.37-40 The possibility that similar interactions may
occur in peripheral mononuclear cells opens interesting perspectives into our results,
especially taking into account that male RA is associated with diminished serum
androgen levels.
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In conclusion: GR-down regulation is not a general phenomenon; it is only present
in (especially postmenopausal) females but not in males. That makes it less likely
that GR-down regulation plays a major role per se in the aetio-pathogenesis of RA.
However, it might be a co-factor, determining the difference in incidence of RA,
being less prevalent in males than in females and determining the difference in the
severity and course of the disease and its response to glucocorticoid therapy. In
addition the question arises if GR expression is different in pre versus post
menopausal patients.
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Abstract
Objective
Low or medium dose prednisone in early rheumatoid arthritis (RA), although with
significant variation in clinical efficacy, reduces the progression of joint damage.
The glucocorticoid receptor (GR) number of peripheral mononuclear cells (PBMC)
might be helpful to predict which patients will respond upon low or medium dose
prednisone and which patients do not or will need higher doses. Therefore we
determined in a double blind placebo controlled study at baseline and yearly the
GR-number in PBMC.
Methods
Eighty-one early RA-patients (disease duration < one year) were included. All patients
fulfilled the ACR criteria and were disease modifying antirheumatic drugs (DMARD)
and glucocortoid-naive. They were randomly assigned to treatment with 10 mg
prednisone daily or placebo. From all patients disease activity (CRP, number of
tender and swollen joints), radiological joint score, bone mineral density and GR-
number in PBMC were measured yearly.
Results
In females the GR-number is up-regulated in time, both in the prednisone as well as
in the placebo group.The same trend was observed in males. No correlations were
found between the GR-number in the prednisone users at the start of their treatment
and change of radiological scores or bone density after two years of treatment. No
correlations were found between the GR-number at the start and the clinical
characteristics after follow-up of two years.
Conclusion
The GR-number of PBMC of early RA patients could not predict which patients
were going to be prednisone responders based on clinical or radiological parameters.
However, the up-regulation of GR-number of PBMC in early RA patients towards
the GR-number of healthy subjects during the first two years of their disease course
seems to reflect a recovery or a compensatory mechanism as an answer upon an
ongoing inflammatory process. This recovery might be not enough to efficiently
control the inflammatory situation.
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INTRODUCTION
Glucocorticoid receptors (GR) are down regulated in rheumatoid arthritis (RA), in
early as well as in long standing disease.1-3 This might reflect an impaired activity of
the hypothalamic-pituitary-adrenal(HPA) axis, and thus play a role in the
aetiopathogenesis of RA.4 Recently, relatively low levels of ACTH and cortisol
were found in relation to Il-6 and TNF in early RA compared with healthy controls.5-7
Therefore, this could be an argument to prescribe glucocorticoids to RA patients
in order to compensate the relative insufficient HPA-axis. Moreover, recent studies
showed that glucocorticoids reduced the progression of joint damage in monotherapy
(10 mg prednisone),8 as well as in combination therapy with disease-modifying
anti-rheumatic drugs (DMARDs).9-11 Biological effects of glucocorticoids at low
and medium doses are mediated by the intracellular GR located in the cytoplasm
of target cells12,13 and the number of intracellular GRs per cell is closely related to
the biological response of glucocorticoids.14 Low dose prednisone is defined as
7.5 mg prednisone equivalents daily or less and medium dose as > 7.5mg, but ≤ 30
mg prednisone daily.15 Clinically, not all patients do respond in the same way:
some patients respond to low doses, while others require higher doses for seemingly
identical clinical situations. The question is whether the number of GR of peripheral
mononuclear cells (PBMC) might be helpful to predict which patient will be
responder upon low or medium dose prednisone and which patient needs higher
doses. In this context it is of interest to mention that in lupus patients suffering
from nephrotic syndrome, a distinct relation of GR level was observed on the
clinical responsiveness with glucocorticoid therapy: improved and recovered patients
have higher GR-number after glucocorticoid therapy than unimproved patients.16
The authors speculate that patients with relative higher GR-number are more
susceptible to glucocorticoids. Steroid resistant asthma patients also show
abnormalities of GR-expression: steroid resistant patients have lower GR-number
and GR-affinity than steroid sensitive patients.17 The aim of this study is to determine
at baseline, but also yearly the GR-number in PBMC upon 10 mg prednisone
therapy as well as upon placebo. The question is: do the early RA patients with
higher GR-number respond better to 10 mg prednisone daily than the patients with
a lower GR-number?
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MATERIAL AND METHODS
Patients
Eighty-one consecutive out-patients with recently diagnosed RA (disease duration<1
year) were included. All patients fulfilled the ACR criteria for RA and were DMARD
and glucocorticoid naive. They were randomly assigned, in blocks of 10, to one of
two treatment groups. One group received 10 mg prednisone daily and one group
placebo. The code of randomisation was broken after 2 years of treatment and
then the prednisone dosage was tapered. Patients were allowed to use non-steroidal
anti-inflammatory drugs (NSAIDs)on demand. After 6 months, sulfasalazine
(2 gram/day) could be prescribed as rescue medication. The decision to add
sulfasalazine was made on clinical grounds (activity of RA). Patient characteristics
were as follows: age varied between 24 and 82 years with a mean (±SD) age of 63
±13 years. The cohort consisted of 29 males (age 61 ±12) years and 52 females
(age 64 ±13 years). Age and sex was equally distributed over the treatment and
placebo groups, as well as IgM rheumatic factor and the number of patients with
erosive disease. From all patients disease activity (CRP, number of tender and
swollen joints), radiological joint score ( joint erosion and joint narrowing score),
bone mineral density and GR-number in PBMC were measured yearly.
Assays
Tender and swollen joints were scored as has been described.18 Blood samples
were collected between 8.00 and 10.00 AM. CRP was determined according to
standard procedures. GR-number was determined as follows: PBMC were isolated
from 40 ml (EDTA) blood using Ficoll-paque density centrifugation.19-22 The cell
suspension was stored overnight at 4°C in Iscove’s medium supplemented with
10% foetal bovine serum that was absorbed with dextran-coated charcoal to remove
free steroid.23 PBMC were centrifugated and washed 2 times with Hanks balanced
salt solution HBSS (without calcium or magnesium; with 3.6 mM NaHCO3, pH7.2,
4°C). Trypan blue staining revealed ≥95% viable cells. A binding curve was made
in duplicate by adding 100 µl 3H-dexamethasone in 7 concentrations  (1.25-40 nM
Amersham; 3.18 TBq/mmol) to 1-2 x106 cells per 100 µl. At the end of the incubation
period (at 24°C with rotation for 90 min), cells were washed 3 times with 20 mM
sodium molybdate dihydrate in HBSS to stabilise receptor-ligand binding,24 followed
by quantification of the bound 3H-dexamethasone using scintillation analysis. The
maximum 3H-dexamethasone binding based on scatchard analysis25,26 revealed the
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number of unoccupied GRs expressed in fmol/million cells, recalculated in absolute
number of receptors per cell. The slope of the line in scatchard analysis reflects the
GR binding affinity(Kd) expressed in nM.
Statistical evaluation
All statistical analyses evaluating the effect of treatment were performed according
to the intention-to-treat- principle. For the 10 patients (4 in the prednisone group
and 6 in the treatment group) who withdrew during the study, the outcomes of the
last measurements were carried forward, with the exception of the radiologic scores.
For comparison between groups, unpaired two-sided Student s T-tests or Mann-
Whitney U tests were used, where appropriate. Statistical significance was defined
at p<0.05. Data are expressed as mean ± SEM. Analyses were performed with the
Number  Cruncher Statistical System 97(NCSS Statistical Software, Kaysville,
Utah).
RESULTS
Both in females and in males the GR-number increased in time, both in the prednisone
as well as in the placebo group (Figure 1). However, only in females it reaches
statistical significance: the GR-number of female prednisone users at t=2 years
versus t=0 years: 10.2 vs. 7.5 fmol/106 cells (pMann-Withney-U = 0.043), the GR-number
of female placebo patients at t=2 years versus t=0 years: 11.0 vs. 6.7 fmol/106 cells
(pMann-Withney-U = 0.000). Leucocytosis did not occur after 1 or 2 years of treatment
with prednisone nor a significant rise of lymphocytes or monocytes. GR affinity(Kd)
after 2 years of treatment was in the female placebo patients significantly higher
compared with the level at base line. No differences in GR affinity were observed
in the female prednisone users nor in the male patients.  CRP and the number of
tender joints did not change significantly in the follow-up years. The number of
swollen joints decreased significantly in the follow-up years.  This illustrates that
the disease activity, which at t=0 was moderate with a mean CRP of 14.2 (3.3) mg/
ml in the female patients and 18.5 (4.8) mg/ml in the male patients, remained about
the same during the follow-up years. No correlations were found between the GR-
number in the prednisone users at t=0 and changes in radiological scores during 2
years of treatment. Neither a correlation was found with changes in BMD after 2
years. However, 4 prednison users developed osteoporotic vertebral fractures.
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Figure 1. GR-number in PBMC in female (upper panel) and male (lower panel) RA
patients treated with 10 mg prednisone daily or placebo. At time (t) = 0 patients were not
yet treated. At t = 1 and t = 2 they were being treated 1 and 2 years, respectively, with
placebo or 10 mg prednisone daily.
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Three of those 4 patients had very low GR-numbers at t=0: 3.3, 3.3, 3.6 and 8.4
fmol/106 cells, which rose to 8.0, 8.7, 11.2 and 10.4 fmol/106 cells, respectively
after 1 year of treatment with 10 mg prednisone daily. Prednisone-responders,
defined as the patients, who did not need SASP rescue medication at t=2 years
(n=27; 13 females,14 males) did not have different GR-number at t=0 compared
with prednisone-non-responders (n=8; 6 females, 2 males).
DISCUSSION
The GR-number of PBMC of early RA patients did not predict which patients
were going to be prednisone responders clinically nor radiologically. However, 3
out of 4 prednisone users who developed osteoporotic vertebral fractures had a
very low GR-number at t=0, which was strongly up-regulated at t=1 year. Whether
this phenomenon is related to steroidosteoporosis needs further investigation. This
cohort of early RA patients had a moderate disease activity, which did not change
much during the follow up years. However progression of radiological joint damage
was inhibited after 2 years of treatment .8 Our results might have been different in
very active early RA patients, who are reaching more complete remission with
higher prednisone dosage. In addition the ratio of the isoforms of the GR, GRβ/
GRα might be of importance in the patients ability to have a good response upon
glucocorticoid therapy.27,28
The GR up-regulation was present in prednisone as well as placebo users and
most prominent in women. In early female RA patients the GR-number at t = 0 is
lower than the GR-number of age and sex matched healthy controls.3 After two
years the GR-number of the female patients with RA is up-regulated to the GR-
number of healthy controls.3 However, this up-regulation probably is not enough
for the inflammatory situation of the RA patient. The increase of GR-number in
PBMC in time was not due to leukocytosis as in our prednisone treated RA patients
no leukocytosis was present after 1 and 2 years, neither a significant rise of
lymphocytes or monocytes. The GR-number is not influenced by age or gender,29
so the increase is not due to two years of aging of our patients either. Up-regulation
of GR seems to reflect a compensatory mechanism of the HPA-axis as an answer
upon an ongoing inflammatory process. This is suggested also by the finding that
higher serum cortisol levels with disappearance of cortisol circadian rhythm is
observed in RA patients with high activity.30 Other studies in a variety of autoimmune
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diseases show GR-down regulation upon glucocorticoid therapy.31,32 However,
this was most obvious at higher doses than the 10 mg prednisone daily used in our
study. In addition, the fact that the HPA-axis seems impaired in early RA might
play a role as well in clarifying that we did not find differences between 10 mg
prednisone and placebo.33 Monotherapy with 10 mg prednisone is disease modifying
in respect to reduced progression of joint damage.8 Combination with another
DMARD gives an even better inhibition of radiological progression.9-11 Since therapy
with 10 mg prednisone gives the same up-regulation of the GR-number as therapy
with placebo, monotherapy with 10 mg prednisone seems not able to fully suppress
disease activity. This might be achieved by adding a DMARD or increasing the
dose of prednisone. Increasing the dose of prednisone might result in responders
and not-responders: in responders the GR-number might be less suppressed than
in non-responders.
Concluding
This is the first study showing follow-up of GR-number of PBMC in early RA
patients upon 10 mg prednisone daily or placebo. The GR up-regulation seems to
reflect a recovery or compensatory mechanism as an answer upon an ongoing
inflammatory process. This recovery might be not enough for the inflammatory
situation at that moment, despite the fact that the progression of radiological damage
is inhibited by 10 mg prednisone daily. The GR-number of PBMC of early RA
patients did not predict which patients were going to be prednisone responders
clinically nor radiologically.
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SUMMARY
For 50 years, glucocorticoids (GC) are used for symptomatic treatment of
rheumatoid arthritis (RA). In the last decade, results from clinical studies of treatment
with GC as additional therapy to long-acting antirheumatic drugs in patients with
early RA suggested also disease-modifying properties of GC in RA.
The aim of this thesis was to investigate disease-modifying properties and side
effects of low-dose GC as monotherapy of patients with previously untreated early
active RA in relation to clinical efficacy, general wellbeing and glucocorticoid
receptors.
All 81 consecutive outpatients who participated in the clinical study had recently
been diagnosed as having early active RA (disease duration less than a year)
according to the ACR criteria, and were therapy naive (no disease-modifying-
antirheumatic drugs [DMARDs] or GC). Age ranged from 24 to 82 years. The
cohort consisted of 52 females and 29 males who attended the outpatient clinics of
the Departments of Rheumatology of the Deventer and Zutphen Hospitals, the
Netherlands. According to a computer-generated randomization at the Pharmacy,
41 patients were allocated to 10 mg prednisone orally daily and 40 to placebo.
Non-steroidal anti-inflammatory drugs (NSAIDs) were allowed in both groups.
After 6 months, sulphasalazine (2 gr. daily) could be prescribed as rescue medication
in both groups. The study duration was 2 years, with an open follow-up third year.
Ten patients dropped out of the study in the first 2 years for reasons not due to
adverse or side effects of the study medication.
At baseline and every 3 months clinical parameters were assessed and every 6
months radiological studies were performed. The following variables were assessed:
early morning stiffness, pain on a visual analogue scale (VAS), general well-being
on a VAS, 28 joint scores for tenderness and swelling, grip strength, disability by a
health assessment questionnaire (Dutch version of the HAQ), C-reactive protein
(CRP) level and radiological scores of hands and feet (vd Heijde modification of
the Sharp method). According to a standardized protocol, adverse and side effects
were documented every 3 months.
In the first 3 months, patients on prednisone showed significant clinical improvement
compared to those taking placebo. At 6 months this effect had disappeared except
for the variables 28 joint score for tenderness and grip strength. However, the use
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of additional therapies (NSAIDs, physiotherapy, paracetamol and local steroid
injections) was significantly lower in the prednisone group. At 2 years, less than
35% of completers in both groups was on sulphasalazine rescue therapy.
From 12 months on, radiological scores showed significantly less progression
of joint damage (erosions and joint space narrowing) in the prednisone group
compared to the placebo group.
No clinically relevant adverse or side effects were observed, except for a higher
incidence of new osteoporotic fractures in the prednisone group. These data are
described and discussed in Chapter 2.
In Chapter 3 we describe in more detail the results of the effect of low-dose GC
on bone and the incidence of fractures. Except for 500 mg calcium supplement
daily, no specific preventive measures were taken at the time the study started back
in 1992. After 2 years prednisone was tapered down and stopped. The effect on
bone was assessed in the first two years and also in the third year. At the start of
the study and every 6 months, X-rays of the twelfth thoracic and all lumbar vertebrae
were scored using the Kleerekoper method, and every year biochemical parameters
of bone metabolism and bone mineral density (BMD) were assessed.
At the start of the study there was one patient in each group with one vertebral
fracture. During the study there was a higher incidence of lumbar vertebral fractures
in the prednisone group than in the placebo group: 7 vs 4 respectively. One patient
in the prednisone group suffered an osteoporotic fracture of the pelvis. In the 2-
year study and the subsequent follow-up year, no other peripheral fractures were
seen in either group. No significant changes from baseline in BMD of the hips and
lumbar spine were seen in either group. The same pattern was observed in the third
year. There was no correlation between changes in serum osteocalcin and BMD.
Low-dose prednisone for patients with early active RA seems to increase the
risk of fractures, despite the observed lack of change in BMD. This confirms the
hypothesis that GC treatment may lead to fractures also via other effects on bone
than decrease of bone mineral density, i.e. via changes in bone strength and structure.
In our analysis a discrepancy was found between the significantly sustained
retardation of joint damage and only transient reduction of disease activity in the
prednisone group and no enduring differences in disease activity variables between
the prednisone group and the placebo group. We investigated whether this
discrepancy also extended to parameters of general wellbeing: the VDF (Dutch
version of the HAQ), the IRGL (Dutch version of the AIMS), the VAS morning
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pain and the VAS general wellbeing. We indeed found almost no differences in
parameters of general wellbeing in both groups. The lack of differences between
the two groups regarding not only variables of disease activity but also variables of
wellbeing is most probably due to a 2-fold increase in the (free) use of additional
therapies (NSAIDs, analgesics, physiotherapy and local steroid injections only if
strictly necessary) in the placebo group compared to the prednisone group. These
results are described in Chapter 4.
In patients with RA of longer duration, glucocorticoid receptor (GR) down-regulation
has been reported without change in cortisol levels. If this down-regulation would
also be present in patients with early RA, it could play a role in the aetiopathogenesis
of RA. In the patients of our study, and age and sex matched healthy controls,
blood samples were taken between 8-10 AM. GR-expression (GR-number and
GR-affinity), serum cortisol levels, erythrocyte sedimentation rate (ESR), CRP,
painful and swollen joints were measured. A significantly lower GR-number was
found in female patients compared with sex and age matched healthy controls, but
not in male patients. Neither in female nor in male patients, correlations were found
between GR-expression and parameters of disease activity nor was there a relation
between GR-expression and serum cortisol levels. So in our study, changes in
GR-expression or serum cortisol were not a general phenomenon, being only present
in females and they were not related to disease activity. From these results it seems
unlikely that GR-expression per se plays a major role in the aetiopathogenesis of
RA. This part of the study is described in Chapter 5.
Because we studied a cohort of patients with DMARD and GC naive early active
RA it was of interest to search for some predictive values for the effect of GC on
the disease. It is common knowledge that not all RA patients respond in the same
way to GC treatment; some do not respond at all, others do at low doses, while
others require larger doses for seemingly identical clinical situations. Therefore, we
investigated the individual response to GC treatment after 1 and 2 years: do
responders differ from non-responders in disease activity and outcome measures?
From the patients of the study blood samples were taken between 8-10 AM. GR-
expression was measured from start and every 12 months and for each individual
compared to parameters of disease activity, general wellbeing and joint damage.
Also, the effects of GC on the proliferative response of peripheral blood
mononuclear cells (PBMC) in those patients were assessed every year. We found
in our study an increase (up-regulation) of the GR-number in time both in females
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and in males, in the prednisone group as well as in the placebo group. This was
most obvious in females. However, no correlations were found between the GR-
number and the radiological scores in the prednisone users after 2 years neither
with  treatment nor with BMD. Prednisone-responders, defined as the patients who
did not use or had not used SASP rescue medication after 2 years, did not have a
different GR-number compared with prednisone-non-responders. So, prediction with
GR-number of the effect of GC was not possible. This is described in Chapter 6.
DISCUSSION
We were able to study benefits and risks of a 2-year treatment with 10 mg prednisone
daily compared to placebo, independent of other therapies, among patients with
early active DMARD-naive RA. This unique clinical setting is unlikely to recur. The
study was designed in 1991 and patients were included from 1992 to 1995.
Nowadays such design in RA, testing an active drug against placebo, would be
considered unethical because we now know joint damage is an early feature of the
disease.1 Therefore, early and aggressive therapy is currently advocated.2-4
We showed significant retardation of joint damage in patients with early RA
treated with 10 mg prednisone daily. There was a sustained reduction in the rate of
joint damage in the second year compared to placebo. Zeidler et al. also saw this
effect in the study with 5 mg prednisolone daily in combination with either gold
sodium thiomalate or methotrexate.5 In the cohort of RA patients of Kirwan and
Hickling, et al. radiologically detected joint damage resumed after discontinuation
of 7.5 mg prednisolone daily in combination with a variety of DMARDs after 2
years.6, 7 In the cohort of RA patients of Boers and Landewé treated with a step-
down combination therapy starting with 60 mg prednisolone there was a sustained
reduction of the rate of radiological progression of joint damage up till 4-5 years.8,
9
 They suggested a ‘window of opportunity’ in the first 2 years of the disease in
which aggressive therapy limits joint destruction over time.
As was expected, patients in the prednisone group experienced significant reduction
in parameters of disease activity in the first 3 months of the study. Remarkably
however, the clinical benefit in this group disappeared between 3 and 6 months
after which there was no difference anymore between the prednisone and the placebo
group, but the use of additional therapies in the prednisone group was about 50%
of that of the placebo group. The increased use of additional therapies in the
placebo group probably counterbalances the beneficial effect of prednisone in the
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prednisone group. After 6 months, sulphasalazine (2 gr daily) could be prescribed
as rescue medication in both groups. Although radiographs of hands and feet were
performed every 6 months, reading took place at the end of the study according to
the protocol (1998). So, without knowledge of possible joint damage and thus
only on clinical grounds, less than 35% of patients at the end of the 2-year study,
equally divided over both groups, was on sulphasalazine. The low prescription
rate for sulphasalazine therapy was apparently influenced by reduced disease
symptoms, due to the free use of additional therapies such as analgesics and
NSAIDs, but the radiologically detected joint damage would in normal daily clinical
practice have warranted earlier intervention.
Results from several recent studies indicate clinical benefit of longer duration
than 3-6 months, although still transient, when combination therapy of DMARDs
(such as sulphasalazine, gold salts and methotrexate) and prednisone was applied.6,
8, 10
 So, for various reasons, prednisone therapy should be added to DMARD
therapy in daily clinical practice.
In our analysis, also in contrast with the significant benefit of prednisone on
radiological joint damage, there were no statistically significant differences in
parameters for wellbeing between both groups during the study. In our view, the
increased use of additional therapies (NSAIDs, analgesics, local steroid injections
and physiotherapy) in the placebo group masked the beneficial effect of prednisone
not only on clinical parameters but also on wellbeing. Up till now, in studies of
patients with RA comparing different treatment strategies the effects of additional
therapies are not evaluated. In future clinical trials, in our view the use of additional
therapies should thus be taken into account and reported upon analysing differences
in effect between two drug therapies.
To put it the other way around, prednisone had a sparing effect on the use of
NSAIDs and other additional therapies. This could explain why in the prednisone
group peptic ulceration occurred less frequently (one patient) than in the placebo
group (two patients): the increased risk of peptic ulceration by the combination of
NSAID and prednisone was counterbalanced by the use of less NSAIDs in the
prednisone group. So, the risk of gastric peptic ulceration when adding prednisone
to the therapy in daily practice could be less than anticipated by the NSAID sparing
effect of prednisone.
In the prednisone group more osteoporotic fractures occurred compared to the
placebo group; the difference however did not reach statistical significance probably
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because of small numbers. In contrast, no significant changes from baseline in
BMD of hips and lumbar spine were seen in either group. The same pattern was
observed in the third year. Apparently, changes in bone strength and structure, in
addition to changes in BMD, may lead to fractures in patients with RA treated with
GC, which confirms earlier reports.11 Due to the observed lack of correlation
between GC-induced osteoporotic fractures and BMD, other techniques assessing
bone strength and structure like quantitative ultrasound should be considered. A
methodological problem of quantitative ultrasound assessment however is that it
cannot be used as follow-up measurements. In contrast to the negative effects on
bone, low-dose GC treatment of patients with RA reduces disease activity and
enhances mobility, effects that are in itself anti-osteoporotic.
The common strategy at the time our study started to prevent secondary
osteoporosis was a daily supplement of 500 mg calcium only. Nowadays prevention
with bisphosphonates in combination with supplementary calcium and vitamin D is
considered the potent anti-osteoporosis strategy of choice in the treatment with GC.
In patients with RA of longer duration, glucocorticoid receptor (GR) down-regulation
has been reported without change in cortisol levels. This could play a role in the
etiopathogenesis of RA. Changes in GR-expression as well as serum cortisol were
not a general phenomenon in our early diagnosed RA patients however, being only
present in females but not in males and  these changes were not related to disease
activity. So, in our view, it seems unlikely that GR-expression plays a major role in
the etiopathogenesis of RA, but it might be a co-factor determining the difference
in incidence of RA, being less prevalent in males than in females.
The GR-number of peripheral blood mononuclear cells (PBMC) of early RA
patients did not predict which patients were going to be prednisone responders,
clinically nor radiologically. GR up-regulation in the first two years of the RA
patient, regardless of the treatment might reflect a compensatory mechanism of the
increasing HPA-axis insufficiency due to the ongoing inflammatory process.
However, this up-regulation might not be enough to efficiently control the
inflammatory situation.
Assessment of the ratio of the isoforms of GR, GR ß/GR a, might be a better
method to predict the patients ability to have a good response upon GC therapy. 12
To investigate the role of GR in the etiopathogenesis of RA and in the prediction of
prednisone responders in future clinical trials assessment of the ratio of the isoforms
of GR is warranted.
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Monotherapy with a 10 mg prednisone regimen in patients with early active DMARD-
naive RA has potent disease modifying properties. So, especially since potential
serious adverse effects are more easily managed today, GC could not only be used
temporarily for complications and exacerbations of RA, to bridge the lag-time for
remission induction of recently started DMARDs and as local injections, but also as
a long-term DMARD regimen in early RA in combination with other DMARDs.13, 14
At the time of the study 10 mg prednisone was considered to be low-dose,
although in daily clinical practice there is now a tendency to regard 7.5 mg prednisone
or even less as low-dose. Due to new insights in mechanism of action of GC,
clinical experience and the results of a meta-analysis of toxicity of GC in patients
with RA, a low-dose regimen is nowadays defined as low as 7.5 mg or less.1, 15, 16
The questions arise if a low-dose prednisone regimen also has joint protective
properties in patients with RA of longer duration and if there is a place for low-
dose prednisone when patients with RA are treated with aggressive DMARDs
strategies (such as methotrexate up to 30 mg weekly) and/or biologicals.
Future studies should thus concentrate first on the question whether 10 mg
prednisone also is beneficial on joint damage if patients are intensively treated with
DMARDs and if the answer is positive, on the search for the lowest dosis of GC in
combination with aggressive DMARD therapy, in order to fully suppress progression
of radiological damage as well as inflammation.
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SAMENVATTING
Reeds meer dan 50 jaar worden glucocorticoïden (GC) toegepast als sympto-
matische behandeling van patiënten met reumatoïde artritis (RA). In het laatste
decennium maken resultaten van klinische trials van behandeling met GC als
toegevoegde therapie bij langwerkende antireumatica bij patiënten in een vroeg
stadium van RA het aannemelijk dat GC naast symptoomverlichting ook
ziektebeïnvloedende eigenschappen bij RA hebben.
Het doel van dit proefschrift is om ziektebeïnvloedende eigenschappen en
bijwerkingen van laaggedoseerde GC als monotherapie bij patiënten met niet eerder
behandelde vroege RA te onderzoeken en te beschrijven in relatie tot klinische
effectiviteit, algemeen welbevinden en GC receptoren.
Bij alle 81 opeenvolgende poliklinische patiënten welke deelnamen aan het onderzoek
was recent vroege actieve RA vastgesteld (ziekteduur minder dan een jaar) volgens
de criteria van het American College of Rheumatology (ACR) en zij waren niet
eerder behandeld met langwerkende ziektebeïnvloedende geneesmiddelen [disease-
modifying antirheumatic drugs (DMARDs)] of GC. De leeftijd varieerde van 24 t/m
82 jaar. De patiëntengroep bestond uit 52 vrouwen en 29 mannen die de poliklinieken
bezochten van de afdeling Reumatologie van de ziekenhuizen in Deventer en Zutphen.
Volgens een door een computer gegenereerde randomisatie in de Apotheek Deventer
Ziekenhuis kregen 41 patiënten dagelijks 10 mg prednison in tabletvorm toegewezen
en 40 patiënten kregen placebo tabletten. In beide groepen was het gebruik van
niet-steroïde pijnstillende en ontstekingswerende middelen toegestaan [non-steroidal
anti-inflammatory drugs (NSAIDs)]. Als ontsnappings-clausule kon in beide groepen
sulfasalazine (2 gram dagelijks) aan de behandeling worden toegevoegd als de
ernst van de klinische verschijnselen van de RA dat noodzakelijk maakte. De duur
van de trial bedroeg 2 jaar met een open nacontrole van 1 jaar. Tien patiënten
verlieten voortijdig het onderzoek in de eerste 2 jaar om redenen die niet samenhingen
met bijwerkingen van de trialmedicatie.
In de uitgangssituatie en daarna iedere 3 maanden werden klinische parameters
gemeten en iedere 6 maanden werden röntgenfoto’s van handen en voorvoeten
gemaakt. De volgende variabelen werden gemeten: duur van stijfheid vroeg in de
ochtend, pijn uitgedrukt op een visuele analoge schaal [visual analogue scale (VAS)],
algemeen welbevinden op een VAS, 28 gewrichtsscore voor pijn bij druk en die
voor zwelling, knijpkracht, functionele beperking middels een vragenlijst dagelijks
functioneren [VDF, een voor Nederland gevalideerde versie van de Health
Assessment Questionnaire (HAQ)], C-reactief proteïne in serum (CRP) en
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radiologische scores van handen en voorvoeten (volgens de vd Heijde modificatie
van de Sharp methode). Volgens een gestandaardiseerd protocol werden bijwerkingen
elke 3 maanden gedocumenteerd.
In de eerste 3 maanden was er een statistisch significante klinische verbetering
waarneembaar bij de met prednison behandelde patiënten ten opzichte van de met
placebo behandelden. Na 6 maanden was dit effect verdwenen met uitzondering
van de 28 gewrichtsscore voor pijn en de knijpkracht. Het gebruik van bijkomende
therapieën (NSAIDs, fysiotherapie, paracetamol en locale steroïdinjecties) was echter
significant lager in de prednison groep. Na 2 jaar gebruikte minder dan 35% van de
patiënten die de trial voltooiden in beide groepen sulfasalazine als ontsnappings-
medicatie.
Vanaf 12 maanden toonden de röntgenfoto’s statisch significant minder
progressie van gewrichtsschade (erosies en gewrichtsspleetversmalling) in de
prednison groep vergeleken met de placebo groep.
Er werden geen klinisch relevante bijwerkingen waargenomen behalve een hogere
incidentie van nieuwe osteoporotische fracturen in de prednison groep. Deze
gegevens worden beschreven en bediscussieerd in Hoofdstuk 2.
In Hoofdstuk 3 beschrijven wij meer gedetailleerd de bevindingen omtrent het
effect van laaggedoseerde GC op het bot en de incidentie van fracturen. Met
uitzondering van 500 mg calcium supplement dagelijks werden geen specifieke
preventieve maatregelen tegen het optreden van osteoporose getroffen ten tijde van
de start van het onderzoek in 1992. Na 2 jaar werd de prednison afgebouwd en
gestaakt. Het effect op het bot werd zowel in de eerste 2 jaar als in het derde jaar
gemeten. Bij de start van de trial en vervolgens iedere 6 maanden werden
röntgenfoto’s vervaardigd van de 12e thoracale en alle lumbale wervels welke na 2
jaar werden beoordeeld volgens de Kleerekoper methode; tevens werden jaarlijks
biochemische parameters van de botstofwisseling gemeten en werd een
botdichtheidsmeting [bone mineral density (BMD)] verricht.
Bij aanvang van het onderzoek was er in iedere groep één patiënt met één
wervelfractuur. Tijdens de trial was er een hogere incidentie van lumbale
wervelfracturen in de prednison groep dan in de placebo groep: 7 vs 4 respectievelijk.
Eén patiënt in de prednison groep kreeg een osteoporotische bekkenfractuur. In de
2-jaarstrial en in het vervolgjaar ontstonden geen andere perifere fracturen in beide
groepen. BMD metingen van heupen en lumbale wervelkolom veranderden niet
significant ten opzichte van de uitgangssituatie in beide groepen. Hetzelfde patroon
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werd in het 3e jaar waargenomen. Er was geen correlatie tussen veranderingen in
osteocalcine in het serum en BMD.
Laaggedoseerde prednisonbehandeling bij patiënten met vroege actieve RA lijkt
het risico van fracturen te verhogen, ondanks het in ons onderzoek waargenomen
ontbreken van een statistisch significante verandering in BMD. Dit bevestigt de
hypothese dat behandeling met GC tot fracturen kan leiden ook via andere effecten
op het bot dan verlaging van de botdichtheid, d.w.z. via veranderingen in botsterkte
en –structuur.
In onze analyse werd een discrepantie gevonden tussen de significante aanhoudende
vertraging van gewrichtsschade enerzijds en slechts voorbijgaande vermindering
van ziekteactiviteit in de prednison groep en geen blijvende verschillen in variabelen
van ziekteactiviteit tussen de prednison groep en de placebo groep anderzijds. Wij
onderzochten of deze discrepantie ook gevonden kon worden in beide groepen in
parameters voor algemeen welbevinden: de VDF, de IRGL (invloed van reuma op
gezondheid en leefwijze, een voor Nederland gevalideerde zelfbeoordelingslijst);
de VAS ochtendpijn en de VAS algemeen welbevinden. Wij vonden inderdaad
vrijwel geen verschillen in parameters voor algemeen welbevinden tussen beide
groepen. Het ontbreken van verschillen tussen de twee groepen voor wat betreft
zowel de variabelen van ziekteactiviteit alsook die voor algemeen welbevinden is
zeer waarschijnlijk toe te schrijven aan verdubbeling van het (vrije) gebruik van
bijkomende therapieën (NSAIDs, analgetica, fysiotherapie en locale steroid injecties
alleen wanneer strikt noodzakelijk) in de placebo groep vergeleken met de prednison
groep. Deze resultaten worden beschreven in Hoofdstuk 4.
Bij patiënten met langer bestaande RA wordt vermindering van het aantal
glucocorticoïd receptoren (GR) in de literatuur gemeld zonder verandering in serum
cortisolspiegels.  Als deze vermindering ook aanwezig zou zijn bij patiënten met
vroege RA, dan zou down-regulatie van GR een rol kunnen spelen in de
etiopathogenese van RA. Bij de patiënten in ons onderzoek en bij voor leeftijd en
geslacht gepaarde gezonde controles werden bloedmonsters afgenomen tussen 8
en 10 uur ‘s ochtends. GR-expressie (GR-aantal en GR-affiniteit), serum cortisol-
spiegels, bloedbezinkingssnelheid van erytrocyten (BSE), CRP en het aantal pijnlijke
en gezwollen gewrichten werden onderzocht. Er werd een significant lager aantal
GR gevonden bij vrouwelijke patiënten in vergelijking met geslacht en leeftijd
gepaarde controles, echter niet bij mannelijke patiënten. Bij vrouwelijke noch
mannelijke patiënten werden correlaties gevonden tussen GR-expressie en parameters
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van ziekteactiviteit, noch was er relatie tussen GR-expressie en serum
cortisolspiegels. Veranderingen in GR-expressie of serum cortisolspiegels waren
in ons onderzoek slechts aanwezig bij vrouwen, was dus geen algemene bevinding
en bovendien was er geen relatie met ziekteactiviteit. Gezien deze bevindingen lijkt
het onwaarschijnlijk dat GR-expressie op zich een belangrijke rol speelt bij het
ontstaan van RA. Dit gedeelte van de trial wordt beschreven in Hoofdstuk 5.
Aangezien wij patiënten met vroege actieve RA bestudeerden die DMARD en GC
naïef waren, was het interessant om naar een mogelijke voorspellende waarde te
zoeken voor het effect van GC op de ziekte. Het is algemeen bekend dat niet alle
RA patiënten op dezelfde wijze reageren op behandeling met GC; sommigen reageren
helemaal niet, anderen doen dat al op lage doses terwijl weer anderen juist hogere
doseringen nodig hebben in ogenschijnlijk vergelijkbare klinische situaties. Daarom
bestudeerden wij de individuele respons op behandeling met GC na 1 en 2 jaar:
verschillen responders van non-responders in GC aantal? Bij patiënten in de trial
werden bloedmonsters afgenomen tussen 8 en 10 uur ‘s ochtends. GR-expressie
werd gemeten bij de start en verder jaarlijks en voor ieder individu vergeleken met
parameters van ziekteactiviteit, algemeen welbevinden en gewrichtsschade. Daarnaast
werden de effecten van GC op de proliferatieve respons van mononucleaire cellen
van het perifere bloed [peripheral blood mononuclear cells (PBMC)] van deze
patiënten ieder jaar onderzocht. Wij vonden in ons onderzoek toename (up-regulatie)
van het aantal GR in de tijd zowel bij vrouwen als bij mannen en zowel in de
prednison- als in de placebo groep. Dit effect is het meest duidelijk bij vrouwen.
Daarentegen werden tussen het aantal GR en de radiologische scores bij de prednison
gebruikers na 2 jaar geen correlaties gevonden noch tussen aantal GR en de aard
van de behandeling, of de BMD. Prednison-responders, gedefinieerd als de patiënten
die geen sulfasalazine als ontsnappingstherapie hoefden te gebruiken tijdens de 2-
jarige trial of als de patiënten die geen sulfasalazine gebruikten na 2 jaar, verschilden
niet wat betreft GR aantal vergeleken met prednison non-responders. Met andere
woorden, voorspelling ten aanzien van het effect van GC aan de hand van het
aantal GR was niet mogelijk. Deze bevindingen worden besproken in Hoofdstuk 6.
DISCUSSIE
Wij konden de voor- en nadelen van een behandeling met 10 mg prednison daags
gedurende 2 jaar vergelijken met placebo, onafhankelijk van DMARDs bij patiënten
met een vroege actieve DMARD-naïeve RA. Het is onwaarschijnlijk dat deze unieke
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klinische setting kan worden herhaald. De trial was opgezet in 1991 en patiënten
werden geïncludeerd van 1992 tot 1995. Tegenwoordig zou een dergelijk onderzoek
met testen van een bewezen effectief geneesmiddel tegen placebo als onethisch
worden beschouwd, aangezien wij nu weten dat gewrichtsschade een vroeg kenmerk
is van de ziekte. Daarom wordt vroege en agressieve behandeling tegenwoordig
aanbevolen.
Wij toonden significante vertraging van gewrichtsschade aan bij patiënten met
vroege RA behandeld met 10 mg prednison dagelijks. De vermindering van de
progressie van de gewrichtsschade hield aan in het 2e jaar in vergelijking met placebo.
Zeidler et al. zagen dit effect eveneens in hun trial met 5 mg prednisolon in combinatie
met het goudzout aurothiomalaat of met methotrexaat. In de groep RA patiënten
van Kirwan en Hickling et al. nam de radiologisch vastgestelde gewrichtsschade
weer toe na staken van 7,5 mg prednisolon dagelijks in combinatie met verscheidene
DMARDs na 2 jaar. In de groep RA patiënten van Boers en Landewé behandeld
met een stapsgewijs afbouwschema met combinatietherapie startend met 60 mg
prednisolon werd aanhoudende vermindering van radiologische progressie van
gewrichtsschade  waargenomen gedurende 4 à 5 jaar. Zij stelden dat er een ‘window
of opportunity’ is in de eerste 2 jaar van de ziekte, waarin agressieve therapie
gewrichtsschade voor langere tijd kan beperken.
Zoals verwacht was er bij onze patiënten in de prednison groep significante
vermindering van ziekteactiviteit in de eerste 3 maanden van het onderzoek. Opvallend
echter verdween de klinische verbetering in deze groep tussen 3 en 6 maanden
vergeleken met de placebo groep. Maar het gebruik van aanvullende behandelingen
was in de prednison groep ongeveer de helft  van dat in de placebo groep. Het
effect van het hogere gebruik van bijkomende therapieën in de placebo groep weegt
waarschijnlijk op tegen het gunstige klinisch effect van prednison in de prednison
groep. Alleen als het klinisch strikt noodzakelijk was kon na 6 maanden sulfasalazine
(2 gram dagelijks) worden voorgeschreven als ontsnappingsmedicatie in beide
groepen. Ofschoon iedere 6 maanden röntgenfoto’s  van handen en voorvoeten
werden gemaakt, vond beoordeling pas plaats aan het eind van de trial volgens het
onderzoeksprotocol (1998). Daarom was, zonder de wetenschap van eventuele
radiologische gewrichtsschade en progressie daarvan en dus uitsluitend op klinische
gronden, minder dan 35% van de patiënten aan het eind van de 2-jaars trial, evenredig
verdeeld over beide groepen, behandeld met sulfasalazine. Het lage voorschrijf-
percentage voor sulfasalazine behandeling was kennelijk beïnvloed door
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gereduceerde ziekteverschijnselen ten gevolge van het vrije gebruik van aanvullende
therapieën waaronder pijnstillers, NSAIDs, fysiotherapie en locale injecties. In de
normale dagelijkse praktijk had de radiologisch vastgestelde gewrichtsschade
ongetwijfeld tot eerdere interventie met DMARDs aanleiding gegeven.
Resultaten van enkele recent uitgevoerde onderzoeken wijzen op klinische
verbetering van langere duur dan 3-6 maanden, als een combinatiebehandeling van
DMARDs (zoals sulfasalazine, goudzouten en methotrexaat) en prednison wordt
toegepast. Daarom dienen DMARDs te worden toegevoegd aan behandeling met
prednison in de dagelijkse klinische praktijk.
Uit onze analyse werden, eveneens in tegenstelling tot het significante gunstige
effect van prednison op gewrichtsschade, geen statistisch significante verschillen
waargenomen in parameters voor algemeen welbevinden tussen de beide groepen
gedurende het onderzoek. Naar ons inzicht maskeerde het toegenomen gebruik van
aanvullende therapieën (NSAIDs, pijnstillers, lokale steroïd injecties en fysiotherapie)
in de placebo groep het gunstige effect van prednison, niet alleen op klinische
parameters maar ook op die van het algemeen welbevinden. Tot nu toe worden de
effecten van aanvullende therapieën in trials met RA patiënten waarin verschillende
behandelstrategieën worden vergeleken niet geëvalueerd. In toekomstige klinische
trials dient naar onze mening met het gebruik van aanvullende behandelingen rekening
te worden gehouden en dient dit gebruik te worden gerapporteerd bij de analyses
van verschillen van effect tussen twee geneesmiddelen.
Men kan ook stellen dat prednison een sparend effect op het gebruik van
NSAIDs en andere aanvullende behandelingen had. Dit zou kunnen verklaren waarom
in de prednison groep er minder vaak (1 patiënt) klinisch relevante peptische ulceratie
optrad dan in de placebo groep (2 patiënten): het verhoogde risico op peptische
ulceratie door de combinatie van NSAID en prednison werd tenietgedaan door het
lagere gebruik van NSAIDs in de prednison groep. Met andere woorden, het risico
van peptische ulceratie wanneer prednison aan de behandeling wordt toegevoegd
kan in de dagelijkse praktijk wel eens lager uitvallen dan verwacht door het NSAID
sparende effect van prednison.
In de prednison groep traden meer osteoporotische fracturen op vergeleken met
de placebo groep; het verschil bereikte echter geen statische significantie,
waarschijnlijk vanwege de kleine aantallen. Daarentegen werden in beide groepen
geen significante veranderingen waargenomen in de BMD van heupen en lumbale
wervelkolom. Hetzelfde patroon werd gezien in het 3e jaar. Kennelijk kunnen
veranderingen in botsterkte- en structuur, naast veranderingen in de BMD, leiden
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tot fracturen bij RA patiënten behandeld met GC, hetgeen eerdere rapporten
bevestigt. Vanwege het waargenomen gebrek aan correlatie tussen GC-geïnduceerde
osteoporotische fracturen en BMD zouden technieken om botsterkte- en structuur
te meten moeten worden overwogen zoals kwantitatieve echografie. Deze techniek
kan echter niet gebruikt worden in follow-up metingen aangezien het ontbreken van
standaardisering een methodologisch probleem is. In tegenstelling tot de negatieve
effecten op het bot vermindert laaggedoseerde GC behandeling bij RA patiënten
de ziekteactiviteit en verhoogt deze therapie de mobiliteit, effecten die osteoporose
tegengaan.
De gebruikelijke strategie ten tijde van de start van ons onderzoek ter voorkoming
van secundaire osteoporose bestond slechts uit een dagelijks supplement van 500
mg calcium. Tegenwoordig worden bisfosfonaten in combinatie met aanvullend
calcium en vitamine D beschouwd als krachtige anti-osteoporose strategie van
keuze bij de behandeling met GC.
Bij patiënten met langer bestaande RA wordt vermindering van het aantal GR
gerapporteerd zonder verandering in serum cortisolspiegels. Dit zou een rol kunnen
spelen in de etiopathogenese van RA. Veranderingen in GR-expressie alsook in
serum cortisolspiegels waren echter geen algemeen verschijnsel bij onze patiënten
met vroege RA. Veranderingen werden alleen bij vrouwen waargenomen en niet bij
mannen en verder toonden deze veranderingen geen relatie met ziekteactiviteit. Dus
lijkt het naar onze mening onwaarschijnlijk dat GR-expressie een belangrijke rol
speelt bij de etiopathogenese van RA, maar het zou een co-factor kunnen zijn die
de incidentie van RA beïnvloedt daar RA minder vaak voorkomt bij mannen dan
bij vrouwen.
Het aantal GR van PBMC bij patiënten met vroege RA voorspelde niet welke
patiënten prednison-responders zouden worden, klinisch noch radiologisch. GR
toename (up-regulatie) in de eerste 2 jaar bij RA patiënten, onafhankelijk van de
behandeling, zou een compensatoir mechanisme van de toenemende hypothalamus-
hypofyse-bijnieras (HHB-as)-insufficiëntie kunnen zijn bij een voortgaand
ontstekingsproces. Deze up-regulatie is echter niet voldoende om het
ontstekingsproces efficiënt te onderdrukken.
Bepaling van de ratio van isovormen van GR, GRβ/GRα, zou een betere
methode kunnen zijn om de kans van een patient te voorspellen op een goede
respons op GC behandeling. Om de rol van GR te bestuderen in de etiopathogenese
van RA en in de voorspelling van prednison-responders is het bepalen van de ratio
van de GR isovormen in toekomstige klinische onderzoeken wenselijk.
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SAMENVATTING EN DISCUSSIE
Monotherapie met een schema van 10 mg prednison bij patiënten met een vroege
actieve DMARD-naïeve RA heeft krachtige ziektebeïnvloedende eigenschappen.
Dus, mede aangezien potentiële ernstige bijwerkingen tegenwoordig beter voorkomen
kunnen worden, zouden GC niet alleen tijdelijk gebruikt kunnen worden bij
complicaties en exacerbaties van RA en om de tijd te overbruggen voor remissie-
inductie van recent gestarte DMARDs optreedt of als locale injecties, maar ook als
langwerkend DMARD regime bij vroege RA in combinatie met andere DMARDs.
Ten tijde van de trial werd 10 mg prednison beschouwd als een lage dosis.
Dankzij nieuwe inzichten in het werkingsmechanisme van GC, klinische ervaringen
en de resultaten van een meta-analyse omtrent toxiciteit van GC bij patiënten met
RA wordt een laaggedoseerd regime tegenwoordig gedefinieerd als 7,5 mg of minder.
    De vraag rijst of een lagere dosis prednison eveneens gewrichtsbeschermende
eigenschappen heeft bij patiënten met langer bestaande RA en of er een plaats is
voor laaggedoseerde prednison behandeling wanneer patiënten met RA worden
behandeld met agressieve DMARD-strategieën (zoals methotrexaat tot 30 mg per
week) en/of biologische middelen (zoals anti-TNF-α en anti-IL-1receptor
antagonisten).
Toekomstige onderzoeken zouden zich eerst moeten concentreren op de vraag
of 10 mg prednison ook een gunstig effect heeft op gewrichtsschade indien patiënten
intensief worden behandeld met DMARDs en als het antwoord positief is, op het
zoeken naar de laagste effectieve dosis GC in combinatie met agressieve DMARD
behandeling teneinde progressie van radiologische gewrichtsschade alsook het
ontstekingsproces zo volledig mogelijk te onderdrukken.
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Velen zijn behulpzaam geweest bij het tot stand komen van dit proefschrift. Allen
wil ik hierbij bedanken en beperk mij tot het noemen van hen die rechtstreeks hierbij
betrokken zijn geweest.
Allereerst alle trouwe reumapatiënten die deelnamen aan het onderzoek en jaarlijks
naar Utrecht reisden; twee van hen beleefden hun mooiste dag uut hun léèven toen
zij bij windkracht 10 op het Centraal Station Utrecht strandden met honderden
andere reizigers en genoten van spontane muziek en soep van het Leger des Heils.
Sommigen waren nog nooit eerder de IJssel over geweest.
In het bijzonder wil ik danken Hans Bijlsma (promotor): voor je visie om mij als
moeder met jonge kinderen een promotieonderzoek toe te dichten in je
onderzoekslijn. Met bewondering heb ik jou een relatief kleine universitaire afdeling
zien opbouwen tot een hoogwaardige kliniek en wetenschappelijk centrum. Jij hebt
in deze lange periode mij steeds gesteund en de rode draad vastgehouden waarin
ik, zonder jou, als een kluwen was geëindigd. Je moet je vermand hebben zo lang in
mij te geloven.
Evenzeer Hans Jacobs (co-promotor): voor je jarenlange intensieve praktische
begeleiding, je meesterlijke vertaling van droge reeksen, getallen en statistische
bevindingen tot de voor mij zo gewenste relevante klinische bevindingen, je soms
tot in herhaling vallende aanwijzingen en kritieken op de door mij geproduceerde
stukken uiteindelijk leidend tot publicatie, je snelle en adequate tekstuele visie, voor
je eigenzinnige en faire manier van communicatie.
Met Dick zag ik Hans&Hans als een duet voor twee heren van wetenschappelijke
stand. Tijdens de regelmatige bijeenkomsten in Utrecht werd ik steeds op scherp
gesteld met als metafoor de Namibische speer die als een machete door mijn epistels
werd gehaald.
Marion Wenting-van Wijk, laborant van het Reumalab (hoofd Floris Lafeber),
UMCU, voor de ontelbare bepalingen en na-bepalingen, grafieken en statistieken;
jouw kunde had ik al meegemaakt bij de promotie van Hans van den Brink waar wij
paranimfen waren. Naast een gezellige tijd dreef ik je soms tot wanhoop, knap dat
je het dan met mij volhield.
Margriet Huisman, internist, gepromoveerd, alsnog nu bijna reumatoloog, voor het
(co-) auteurschap van de artikelen over receptoren en up(s)-en down regulatie; je
hebt overzicht over de stof en ik waardeer je kordate optreden.
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Ank Jacobs-van Bree voor datamanagement; jij wist eindeloos geduldig en vriendelijk
mijn entropische notities om te zetten in bruikbare geordende reeksen op datum.
UMCU, voor het verwerken van series e-mails, telefoons, printwerk en verzenden
en ontvangen van artikelen; Gerrie, dit hoofdstuk hebben we nu afgesloten, zeg dat
maar tegen Jeanette.
Het Reum-A-team Deventer en Zutphen: Margreeth Kamphuis, doktersassistente
en Diane Oosterbroek (nu reumaconsulent) voor het vanaf het begin liefderijk
organiseren van mijn spreekuren, het begeleiden van de patiënten en het eindeloos
opzoeken van gegevens en dossiers en de andere leden van het team: Gerrie, Sandra,
Christa, Adrie, Anne, Marieke (en destijds Ina); de lunch op maandag blijft heilig.
Gré Hanko, toenmalig secretaresse polikliniek Reumatologie, Utrecht, voor haar
warme bejegening en voor het opsporen van zoekgeraakte Sallandsche en
Achterhoekse patiënten in het mondaine AZU; vrolijk ondersteund door Ida, Ilse
en Chantal.
Cees Haaring, lay-out wizzard, voor je prettige en efficiënte werkwijze; al bij de
eerste hoofdstukken bracht jij mijn boek tot leven.
Ziekenhuis, voor het bereiden, randomiseren en distribueren van de onderzoeks-
medicatie.
Dick Hofman, reumatoloog, je kwam graag vanuit Hilversum naar Deventer voor
het nauwgezet scoren van de wervelkolomfoto’s afgewisseld met gezellige
momenten.
Elise Brouwer-Kuiper, radioloog, voor het scoren van de röntgenfoto’s van handen
en voeten in het laatste jaar van je opleiding buiten de normale werktijden tot ’s
avonds laat en in het weekend, soms zelfs met dochter.
Ike Nuver-Zwart, reumatoloog in de Maatschap Deventer-Zutphen, voor het
includeren van patiënten en voor het stug volhouden dat ik het werk moest afmaken.
Marian Möller, bibliothecaris van de Mediatheek Deventer Ziekenhuis, voor je immer
enthousiaste graafwerk op wetenschappelijk terrein en voor het opsporen van de
levenswandel van Raoul Dufy, je werd net zo door het verhaal en zijn werk gegrepen
als ik.
Bavo Ghuijs (Deventer), Marthijs Berentschot (Zwolle) en Gerrit Berends
(Terwolde), jullie zijn mijn lokale software prinsen.
Paul Lamberts, Ben Ploeger en Coen Teunissen, apothekers van het Deventer
Gerrie de Kruijf, secretaresse van de afdeling Reumatologie & Klinische Immunologie,
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Edwin Beijer en Lenka Kerstens van MSD voor jullie extra en persoonlijke
inspanningen o.a. bij het tot stand komen van de buitenkant van dit proefschrift.
Jannes van Everdingen, creatief schrijver, uitgever en broer; een deel van mijn
onderwerp hoort ook tot de medische misvattingen.
Diederike van Beuningen, paranimf vanwege lange en bijzondere vriendschap; je
staat nu als stuurvrouwe voor mij even aan wal. Hoewel zonder medische achtergrond
stelde je vaak rake vragen over mijn onderzoek, dank voor je aanhoudende
belangstelling.
Louise van Everdingen voor je aanstekelijke power of life.
Mijn ouders; mijn vader, huidarts, heeft mijn eerste jaren Geneeskunde nog intens
meegemaakt; mijn moeder, jij zorgde voor een warm nest en je hebt na het overlijden
van Huib het voor elkaar gekregen dat ik mijn studie kon vervolgen.
Mijn kinderen:
Feike, met opgewekte en inventieve energie heb jij je voor mij ingezet rondom de
promotie, de man van de org-ideëen.
Wibbien, de krachtige en punctuele wijze waarmee jij je hebt opgeworpen als co-
editor bij de afronding van dit boekje vormde een welkom tegenwicht tegen mijn
momenten van nonchalance.
Jet, als ik bij jou in Groningen ben voel ik me de meest welkome gast.
Pleun, als het er echt om gaat kan ik op je rekenen en in jouw aanwezigheid voel ik
me altijd vrolijk.
Jaap, de ongelooflijke wijze waarop je mij met veel humor en internationaal toneel
van het werk kan houden heeft mij er niet van weerhouden dit werk te klaren.
en
Dick, jij bent mijn paradenimf.
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POEM BY RAOUL DUFY, PARIS, APRIL 1950
I have long tried to capture
The motion of race horses and
regattas
The movement of the orchestra
As musicians chase the notes
In concertos of yellow and red
I have painted electricity
With dynamos and electrons moving
at the speed of light
Craving more speed I released my
canvases
To color silk scarves and dresses
And finally saw my work sail with the
wind
Now my hands are splinted
And I have become disjointed
An old man whose hands will not
obey his heart
Rheumatism loosened Renoirs brush
from his grasp
And his son bound the bristles to the
hollow of his hand
But Dr Perles has assured me
That the new remedy, cortisone and
ACTH
Will release the bonds
Of the arthritis that have held me in
place
My only wish to draw freehand
Following the wind
Flowers that beckon me
And capturing them
In a vase of Anemones
Yesterday the invitation arrived
Drawing me to Dr Homburger
And his hospital in America
Tomorrow I sail to Boston in search
Of my hands
Forty years ago I painted with Braque
at Estaque
The cubist edges cut too deep into
my palette
And I joined Matisse and became a
Fauve
I covered my canvases only with the
colors that I could feel
Avoiding those that I could see
Unsatisfied I traveled to Munich,
Normandy, Marseille
Saw the terrible women of Avignon
And found myself on the Riviera in
Venice
Fifteen years ago the attacks began
Disfiguring my hands
As if I were painting with leaden
gloves
I sought gold injections
Underwent spinal manipulations
And made a pilgrimage to a Spanish
spa
Yet my hands drew still
I continued studies in my mind
Waiting for the time
When my brush could be awakened
To decorate the canvas
With arabesques and flourishes
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Amalia Augusta van Everdingen werd geboren op 21 juni 1947 te Dordrecht. Zij
bezocht het Johan de Witt Gymnasium waar zij het diploma Gymnasiumβ behaalde
in 1966. Vanaf 1966 studeerde zij Geneeskunde aan de Rijks Universiteit te Leiden
alwaar in 1973 het artsexamen werd behaald. Van 1969-1971 was zij werkzaam als
kandidaatsassistent op de afdeling Beademing (Drs JJ van Zanten). In 1972 behaalde
zij het Amerikaans artsexamen van de Verenigde Staten, het ECFMG (Educational
Council for Foreign Medical Graduates), te ‘s-Gravenhage. Een deel van de co-
assistentschappen werd doorlopen in 1973 in Paramaribo, Suriname, waar zij tevens
werkzaam was in een leprakolonie. Van 1973-1976 was zij als assistent geneeskundige
werkzaam op de afdelingen Longziekten (Prof Dr J Swierenga), Radiologie (Prof
Dr AE van Voorthuisen), Radiotherapie (Prof Dr P Thomas) en Heelkunde (Prof
Dr M Vink) van het Academisch Ziekenhuis te Leiden. Van 1976-1986 was zij
waarnemend huisarts in Noordwijk, Voorhout en Twello. Van 1986 tot heden is zij
als arts en wetenschappelijk medewerker verbonden aan de afdeling Reumatologie
van het Deventer Ziekenhuis te Deventer en die van het Gelre Ziekenhuis te Zutphen
(Drs DR Siewertsz van Reesema en Drs HH Nuver-Zwart, reumatologen) en vanaf
1989 tevens aan de afdeling Reumatologie en Klinische Immunologie van het
Universitair Medisch Centrum Utrecht (Prof Dr JWJ Bijlsma) waar zij vanaf 1992,
mede dankzij subsidie van het Nationaal Reumafonds, in staat is wetenschappelijk
onderzoek te verrichten oa. naar de invloed van glucocorticoïden bij de behandeling
van vroege reumatoide artritis.
Zij ondersteunt de kliniek Ndlovu Medical Center (NMC) van Drs H Tempelman
en Drs P Schrooder, huisartsen te Elandsdoorn, Mpumalanga, Zuid Afrika.
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